 
 
 
 
 
CLINICAL STUDY PROTOCOL
 
 
A Multicenter, Randomized, Double
-
Masked, Placebo
-
Controlled, Parallel
-
Group Study 
to Evaluate the Efficacy 
and Safety 
of APP13007 for the Treatment of Inflammation and 
Pain after Cataract Surgery
.
 
 
PROTOCOL NUMBER:  
CPN
-
30
1
 
 
Protocol 
Version
:
 
1.
3
 
(Amendment 1)
 
Version Date:
 
18
 
May 2021
 
Study Sponsor:
 
 
Formosa Pharmaceuticals, Inc.
 
8F
-
6, No. 57, Fuxing North Road
 
Songshan
 
Dist
rict
, Taipei
 
Taiwan 10
5
, Republic of China
 
Sponsor US 
Representative:
 
 
 
 
Contract Research 
Organization for Study 
Management and 
Monitoring:
 
 
 
 
Study Medical Monitor:
 
 
 
 
 
 
 
CONFIDENTIAL INFORMATION
 
This document is the property of Formosa Pharmaceuticals, Inc.
 
 This document and 
any and all information contained herein has to be considered and treated as strictly confidential. This document shall 
be used only for the purpose of the disclosure herein provided. No disclosure or publication shall
 
be made without the 
prior written consent o
 

Clinical Study Protocol:  CPN-
301
 
Formosa Pharmaceuticals, Inc. 
APP13007 
 
Version 
1.3 
(Amendment 1)
 
CONFIDENTIAL 
Page 
2 
of 
89
 
APPROVAL SIGNATURE [CONTACT_612673] 
 
 
 
 
18 May 2021
 
 
 
Date
 
Chief Medical Officer
 
 
 
 
 
 
 
 
18 May 2021
 
 
 
 
Date
 
Biostatistician
 
 
 
 
 
 
 
 
 
 
______________________
 
 
May 18, 2021
 
 
 
Date
 
Chief 
Development 
Officer
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Clinical Study Protocol:  CPN
-
301
 
Formosa Pharmaceuticals, Inc.
 
APP13007
 
.
 
 
Version 1.
3 
(Amendment 1)
 
CONFIDENTIAL
 
Page 
3 
of 
89
 
PRINCIPAL INVESTIGATOR’S AGREEMENT
 
I have read and understand the contents of this clinical Protocol No. 
CPN
-301 (Version 1.3, 
Amendment 1) 
dated 
[ADDRESS_812121] the Study in 
accordance with 
this protocol, 
current Good Clinical Practices and applica
ble FDA regulatory 
requirements:
 
Name [CONTACT_789]:
 
[CONTACT_5627]:
 
 
Title:
 
 
Clinic:
 
 
Address:
 
 
Phone:
 
 
 
 
 
 
 
Signature
 
 
[CONTACT_612674]:  CPN
-
301
 
Formosa Pharmaceuticals, Inc.
 
APP13007
 
 
 
Version 1.
3 
(Amendment 1)
 
CONFIDENTIAL
 
Page 
[ADDRESS_812122] OF SPONSOR REPRESENTATIVE 
 
 
 
 
 
 
 
 

Clinical Study Protocol:  CPN
-
301
 
Formosa Pharmaceuticals, Inc.
 
APP13007
 
 
 
Version 1.
3 
(Amendment 1)
 
CONFIDENTIAL
 
Page 
5
 
of 
89
 
168B
 
CHANGES IN PROTOCOL AMENDMENT 1
 
This protocol is being amended 
to:
 

 
Clarify 
the permitted and 
prohibited medications
 
based on feedback from investigators 
and to permit vaccinations/immunizations
 

 
Indicate that prohibited medications preferably should be withheld until after the POD22 
assessments
 

 
Correct minor formatting errors
 
This amendment applies
 
to all clinical site
s
 
participating in
 
this study.
 
 
TABLE OF 
C
HANGES IN AMENDMENT 1
 
Protocol Section
 
Original Text
 
Amended Text (Bolded)
 
Synopsis 
and Section 4.3 
(
Exclusion 
Criterion 7
) and 
Section 
5.4.2
 
Subjects receiving therapy for 
macular degeneration (in either 
eye) with Eylea
®
 
(aflibercept), 
Avastin
®
 
(bevacizumab), 
Lucentis
®
 
(ranibizumab) or 
Visudyne
®
 
(verteporfin) are 
excluded
 
Subjects receiving therapy for 
macular degeneration (in 
either 
eye) with Eylea
®
 
(aflibercept), 
Avastin
®
 
(bevacizumab), 
Lucentis
®
 
(ranibizumab), 
Beovu
®
 
(brolucizumab
-
dbll)
 
or Visudyne
®
 
(verteporfin) are 
excluded
 
Synopsis 
and Section 4.3 
(
Exclusion 
Criterion 7
) and 
Section 
5.4.2
 
 
ii. PROKERA (preserved 
amniotic membrane) is 
excluded from 1 year prior to 
the Screening visit to the end 
of the study.
 
Synopsis 
and Section 4.3 
(
Exclusion 
Criterion 7
) and 
Section 
5.4.2
 
from the beginning of the 
‘Washout’ period in “List of 
Prohibited Medications” until 
after the POD15 assessments
 
from the beginning of the 
‘Washout’ period in “List of 
Prohibited Medications” until 
after the POD15 assessments, 
but preferably until 
after the 
POD22 assessments
 
Synopsis 
and Section 4.3 
(
Exclusion 
Criterion 7
) and 
Section 
5.4.2
 
Anti
-
inflammatory agents, 
analgesics (including opi[INVESTIGATOR_2438], 
narcotics, nonsteroidal anti
-
inflammatory drugs (NSAIDs), 
aspi[INVESTIGATOR_248], acetaminophen and 
other pain medications) or 
immune
-
modulating agent
s 
systemically or in either eye 
from the beginning of the 
‘Washout’ period in the “List 
of Prohibited Medications” 
Anti
-
inflammatory agents, 
analgesics (including op
ioids, 
narcotics, nonsteroidal anti
-
inflammatory drugs (NSAIDs), 
aspi[INVESTIGATOR_248], acetaminophen and 
other pain medications) or 
immune
-
modulating agents 
systemically or in either eye 
from the beginning of the 
‘Washout’ period in the “List 
of Prohibited Medications”
 
Clinical Study Protocol:  CPN
-
301
 
Formosa Pharmaceuticals, Inc.
 
APP13007
 
 
 
Version 1.
3 
(Amendment 1)
 
CONFIDENTIAL
 
Page 
6
 
of 
89
 
until after the POD15 
assessments. 
Note: 
acetaminophen is permitted on 
the day of surgery.
 
until after the POD15 
assessments, 
but preferably 
until after the POD22 
assessments
. 
Note: 
(i)
 
acetaminophen is permitted 
on the day of surgery; (ii) 
immunizations/vaccinations 
are permitted before and 
during the study.
 
Synopsis
 
and Section 4.3 
(
Exclusion 
Criterion 7
) and 
Section 
5.4.2
 
Systemic anti
-
inflammatory 
agents including 
acetaminophen, NSAIDS, 
acetylsalicylic acid (aspi[INVESTIGATOR_248]), 
and Lifitegrast.  
 
Note: (i
) Use of acetylsalicylic 
acid for cardiovascular 
prophylaxis (i.e., 81 mg dose 
QD) is allowed if dosage has 
been stable for at least 30 days 
prior to surgery and will 
remain stable for the duration 
of the study.  (ii) 
Acetaminophen may be 
administered as n
eeded pre
-
 
and post
-
operatively on the day 
of surgery.
 
Systemic anti
-
inflammatory 
agents including 
acetaminophen, NSAIDS, 
acetylsalicylic acid (aspi[INVESTIGATOR_248]), 
and Lifitegrast.  
 
Note: (i) Use of acetylsalicylic 
acid for cardiovascular 
prophylaxis (i.e., 81 mg d
ose 
QD) is allowed if dosage has 
been stable for at least 30 days 
prior to surgery and will 
remain stable for the duration 
of the study.  (ii) 
Acetaminophen may be 
administered as needed pre
-
 
and post
-
operatively on the day 
of surgery, 
(iii) Over
-
the
-
Count
er preparations such as 
Fish Oils, Turmeric and 
Ginseng that may have mild 
anti
-
inflammatory effects are 
allowed.
 
Synopsis 
and Section 4.3 
(
Exclusion 
Criterion 7
) and 
Section 
5.4.2
 
Systemic analgesics/pain 
relievers such as gabapentin, 
pregabalin, opi[INVESTIGATOR_612594]/pain 
relievers such as gabapentin, 
pregabalin, opi[INVESTIGATOR_612595]: Marijuana/CBD
-
containing products have the 
same washout restrictions as 
“Systemic Analgesics” 
because they can affect pain 
perception
 
Synopsis 
and Section 4.3 
(
Exclusion 
Criterion 7
) and 
Section 
5.4.2
 
Medica
tions for benign 
prostatic hypertrophy (BPH) 
(e.g., finasteride). 
Note: 
Investigators should consider 
excluding subjects who are 
taking or have taken 
α
-
1 
Medications for benign 
prostatic hypertrophy (BPH) 
(e.g., finasteride, 
α
-
1 
adrenergic receptor 
antagonists
) 
are allowed 
based on the judgment of the 
Clinical Study Protocol:  CPN
-
301
 
Formosa Pharmaceuticals, Inc.
 
APP13007
 
 
 
Version 1.
3 
(Amendment 1)
 
CONFIDENTIAL
 
Page 
7
 
of 
89
 
adrenergic receptor 
antagonists (eg. 
tamsulosin, 
silodosin, alfuzosin
) because of 
the risk of 
intraoperative floppy 
iris syndrome.
 
 
[28 Days]
 
investigator
. 
Note: 
Investigators should consider
 
the potential risk of 
intraoperative floppy iris 
syndrome in subjects 
who are 
taking or have taken 
α
-
1 
adrenergic receptor 
antagonists (eg. 
tamsulosin, 
silodosin, alfuzosin
).
 
 
[Stable dose for 
28 days
]
 
Synopsis 
and Section 4.3 
(
Exclusion 
Criterion 7
) and 
Section 
5.4.2
 
Stable doses of anticholinergics 
and antidepressants are 
allowed. Alterations of the dose 
of a
nticholinergics and 
antidepressants (other than for 
prn use as a sleep aid) may be 
allowed following consultation 
with the Study Medical 
Monitor. Anticholinergic eye 
drops used to dilate the eye are 
allowed.  Systemic 
anticholinergic drugs are 
allowed on t
he day of surgery. 
 
 
[90 days if altering the dose]
 
Additional new text
 
 
Note 1
 
For anti
-
depressants used to 
treat depression: (i) 
Medication must not be 
washed
-
out for the purpose of 
enrollment in the study; (ii) 
Stable doses of anti
-
depressants are allow
ed; (iii) 
When the dose of an anti
-
depressant has been altered, 
the subject needs to be on the 
stable altered dose for at least 
90 days prior to the day of 
surgery (Day 0).
 
 
Note 2
 
For anti
-
depressants used to 
treat pain: (i) The 
instructions provided for 
systemic analgesics/pain 
relievers apply, viz. at least a 
14 day washout of the 
medication is required prior 
to the day of surgery (Day 0) 
continuing until the POD15 
assessments have been 
completed.
 
 
[See Note 1 and Note 2]
 
Synopsis 
and Section 4.3 
(
Exclusion 
Criterion 14
) 
 
14. Have corneal dystrophies or 
dysthyroid ophthalmopathy in 
the study eye.
 
14. Have corneal dystrophies, 
includin
g corneal guttae and 
Fuchs’ dystrophy
, or 
dysthyroid ophthalmopathy in 
the study eye.
 
Clinical Study Protocol:  CPN
-
301
 
Formosa Pharmaceuticals, Inc.
 
APP13007
 
 
 
Version 1.
3 
(Amendment 1)
 
CONFIDENTIAL
 
Page 
8
 
of 
89
 
Section 
6.2.2
 
Day of Surgery
 
On Day 0, the surgeon will 
perform his/her routin
e cataract 
surgical procedure using 
phacoemulsification and 
implantation of a posterior 
chamber intraocular lens in the 
operated eye following the 
surgeon’s usual pre
-
operative, 
operative, and post
-
operative 
procedures (with the exception 
of avoiding use o
f prohibited 
medications).  
 
On Day 0, the surgeon will 
perform his/her routine cataract 
surgical procedure using 
phacoemulsification and 
implantation of a posterior 
chamber intraocular lens in the 
operated eye following the 
surgeon’s usual pre
-
operative, 
operative, and post
-
operative 
procedures (with the exception 
of avoiding use of prohibited 
medications).  
Aqueous 
release procedures are not 
permitted.
 
 
 
Clinical Study Protocol:  CPN
-
301
 
Formosa Pharmaceuticals, Inc.
 
APP13007
 
 
 
Version 1.
3 
(Amendment 1)
 
CONFIDENTIAL
 
Page 
[ADDRESS_812123] Surgery
 
................................
...............................
 
25
 
1.2.3
 
Rationale for Development of APP13007
 
................................
................................
...............
 
26
 
1.3
 
Nonclinical Studies
................................
................................
................................
..................
 
26
 
1.3.1
 
Primary Pharmacology
 
................................
................................
................................
............
 
26
 
1.3.2
 
Pharmacokinetics
................................
................................
................................
.....................
 
26
 
1.3.3
 
Toxicology
 
................................
................................
................................
..............................
 
27
 
1.4
 
Human Studies
 
................................
................................
................................
........................
 
27
 
1.4.1
 
CPN
-
201: A Phase [ADDRESS_812124] Surgery
 
.............
 
27
 
[IP_ADDRESS]
 
Safety Results
 
................................
................................
................................
..........................
 
28
 
[IP_ADDRESS]
 
Efficacy Results
 
................................
................................
................................
.......................
 
28
 
[IP_ADDRESS]
 
Conclusion
 
................................
................................
................................
...............................
 
29
 
1.4.2
 
CPN
-
102: A Phase 1 Pharmacokinetic Study in Healthy Subjects
 
................................
.........
 
29
 
[IP_ADDRESS]
 
Safety Results
 
................................
................................
................................
..........................
 
29
 
[IP_ADDRESS]
 
Pharmacokinetic Results
 
................................
................................
................................
.........
 
29
 
1.4.2.
3
 
Conclusion
 
................................
................................
................................
...............................
 
30
 
1.5
 
Risk/Benefit Assessment
 
................................
................................
................................
.........
 
30
 
1.5.1
 
Potential Risks
 
................................
................................
................................
.........................
 
30
 
[IP_ADDRESS]
 
Potential Risks Anticipated Based on Results from the GLP Rabbit Toxicology Studies 
with APP13007
................................
................................
................................
........................
 
30
 
[IP_ADDRESS]
 
Potential Risks Anticipated Based on Results from the Human Studies with APP13007
 
......
 
30
 
[IP_ADDRESS]
 
Potential Risks Associated with the Use of CP in the Treatment of Corticosteroid
-
Responsive Dermatoses
 
................................
................................
................................
...........
 
31
 
[IP_ADDRESS]
 
Potential Class
-
Related Ocular Risks Associated with Corticosteroid Therapi[INVESTIGATOR_612596]
 
................................
.........
 
31
 
[IP_ADDRESS]
 
Potential Risks Associated with the APP13007 Formulation
 
................................
.................
 
32
 
1.5.2
 
Risk Mitigation Plan
 
................................
................................
................................
................
 
33
 
1.5.3
 
Contraindications
................................
................................
................................
.....................
 
33
 
1.5.4
 
Potential Benefits
 
................................
................................
................................
....................
 
33
 
1.5.5
 
Assessment of Potential Risks and Benefits
 
................................
................................
............
 
34
 
 
STUDY OBJECTIVES AND ENDPOINTS
 
................................
................................
..........
 
38
 
 
STUDY DESIGN
 
................................
................................
................................
....................
 
40
 
3.1
 
Study Design Overview
 
................................
................................
................................
...........
 
40
 
3.2
 
Study Visit Overview
 
................................
................................
................................
..............
 
40
 
3.2.1
 
Study Visits and Procedures
 
................................
................................
................................
....
 
40
 
3.
2.2
 
Contingencies relating to the COVID
-
19 Pandemic
 
................................
...............................
 
41
 
3.3
 
Rationale for Study Design
 
................................
................................
................................
.....
 
41
 
3.3.1
 
Rationale for Number of Subjects to be Randomized
 
................................
.............................
 
41
 
Clinical Study Protocol:  CPN
-
301
 
Formosa Pharmaceuticals, Inc.
 
APP13007
 
 
 
Version 1.
3 
(Amendment 1)
 
CONFIDENTIAL
 
Page 
10
 
of 
89
 
3.3.2
 
Rationale for the Primary Efficacy Endpoints
 
................................
................................
.........
 
41
 
3.3.3
 
Rationale 
for Dosing Regimen
 
................................
................................
................................
 
42
 
 
STUDY POPULATION
 
................................
................................
................................
..........
 
43
 
4.1
 
Number of Subjects
 
................................
................................
................................
.................
 
43
 
4.2
 
Inclusion Criteria
 
................................
................................
................................
.....................
 
43
 
4.2.1
 
Additional Inclusion Criteria on Postoperative Day (POD) 1/Day of Randomization 
(Visit 2)
 
................................
................................
................................
................................
...
 
44
 
4.3
 
Ex
clusion Criteria
 
................................
................................
................................
....................
 
44
 
 
STUDY DRUG AND TREATMENTS
 
................................
................................
..................
 
47
 
5.1
 
Study Drug Administration
 
................................
................................
................................
.....
 
47
 
5.1.1
 
Study Drug Description
 
................................
................................
................................
...........
 
47
 
5.1.2
 
Study Drug Dosing and Administration
 
................................
................................
..................
 
48
 
[IP_ADDRESS]
 
Dispensing and R
eplacing Study Drug
 
................................
................................
....................
 
48
 
[IP_ADDRESS]
 
Subject Diaries
 
................................
................................
................................
........................
 
48
 
[IP_ADDRESS]
 
Study Drug Compliance
 
................................
................................
................................
..........
 
49
 
[IP_ADDRESS]
 
Study Treatments
 
................................
................................
................................
.....................
 
49
 
5.1.2.
5
 
Study Drug Dosing
 
................................
................................
................................
..................
 
49
 
5.2
 
Study Drug Return and Accountability
 
................................
................................
...................
 
50
 
5.3
 
Masking and Unmasking
 
................................
................................
................................
.........
 
50
 
5.4
 
Prior/Concomitant Therapy and Rescue Medication
................................
...............................
 
[ADDRESS_812125] Number
 
................................
................................
................................
.............
 
55
 
6.2
 
Description of Study Visits
 
................................
................................
................................
.....
 
55
 
6.2.1
 
Visit 1 
-
 
Screening
 
................................
................................
................................
...................
 
55
 
6.2.2
 
Day of Surgery (Day 0)
 
................................
................................
................................
...........
 
56
 
6.2.3
 
Visit 2 
-
 
POD1 (Day of Randomization)
 
................................
................................
.................
 
56
 
6.2.4
 
Visit 3 (POD4 ± 1) and Visit 4 (POD8 ± 1)
 
................................
................................
............
 
[ADDRESS_812126] on POD14
 
................................
................................
..........................
 
57
 
6.2.6
 
Visit 5 (POD15 + 1)
 
................................
................................
................................
................
 
58
 
6.2.7
 
Visit 6 (POD22 ± 2)
 
................................
................................
................................
................
 
58
 
6.2.8
 
Early Termination/Withdrawal
 
................................
................................
................................
 
[ADDRESS_812127] Early Termination (Withdrawal)
 
................................
................................
................
 
[ADDRESS_812128] of Efficacy Assessments
 
................................
................................
................................
..
 
61
 
Clinical Study Protocol:  CPN
-
301
 
Formosa Pharmaceuticals, Inc.
 
APP13007
 
 
 
Version 1.
3 
(Amendment 1)
 
CONFIDENTIAL
 
Page 
11
 
of 
89
 
7.2.2
 
Procedures for Assessment of Efficacy Endpoints
 
................................
................................
..
 
61
 
[IP_ADDRESS]
 
Anterior Chamber Cell Count and Anterior Chamber Flare
 
................................
...................
 
61
 
[IP_ADDRESS]
 
Subject
-
Rated Ocular Pain Assessment
 
................................
................................
...................
 
62
 
[IP_ADDRESS]
 
Best Corrected Visual Acuity
 
................................
................................
................................
..
 
[ADDRESS_812129] of Safety Assessments
 
................................
................................
................................
......
 
62
 
[IP_ADDRESS]
 
Assessment of Adverse Events
 
................................
................................
................................
 
63
 
[IP_ADDRESS]
 
ETDRS Best Corrected Visual Acuity Measurement by [CONTACT_25715][INVESTIGATOR_202324]
 
..............................
 
63
 
[IP_ADDRESS]
 
Slit Lamp Biomicroscopy
 
................................
................................
................................
........
 
64
 
7.3.2
 
IOP Measurement
 
................................
................................
................................
....................
 
64
 
7.3.3
 
Dilated Ophthalmoscopy
 
................................
................................
................................
.........
 
6
5
 
 
ADVERSE EVENTS
 
................................
................................
................................
..............
 
66
 
8.1
 
Definition of Adverse Events (AEs)
................................
................................
........................
 
66
 
8.1.1
 
Subjects who are Randomized
................................
................................
................................
.
 
66
 
8.1.2
 
Subjects who are Not Eligible for Randomization (Screen Failures)
 
................................
......
 
67
 
8.2
 
Definition of Serious Adverse Events (SAEs)
 
................................
................................
........
 
67
 
8.3
 
Classification of an Adverse Event
 
................................
................................
.........................
 
68
 
8.3.1
 
Severity of Event
 
................................
................................
................................
.....................
 
68
 
8.3.2
 
Relationship to Ocular Surgical Procedure or Study Drug
 
................................
......................
 
68
 
8.3.3
 
Expectedness
 
................................
................................
................................
...........................
 
69
 
8.3.4
 
Action Taken with Study drug
 
................................
................................
................................
 
69
 
8.3.5
 
Adverse Event Outcome
 
................................
................................
................................
..........
 
70
 
8.4
 
Adverse Event Follow
-
Up
 
................................
................................
................................
.......
 
70
 
8.5
 
Overdose/Under
-
dose for Assessment of Compliance
 
................................
............................
 
70
 
8.5.1
 
Overdose
 
................................
................................
................................
................................
..
 
70
 
8.5.2
 
Under
-
dose
 
................................
................................
................................
..............................
 
71
 
8.6
 
Pregnancies
 
................................
................................
................................
..............................
 
71
 
8.7
 
Serious Adverse Event Reporting
 
................................
................................
...........................
 
72
 
8.7.1
 
Reporting Requirements
 
................................
................................
................................
..........
 
72
 
8.7.2
 
Reporting of Serious and Unexpected Suspected Adverse Reactions (S[LOCATION_003]R
S
)
 
..................
 
[ADDRESS_812130]
................................
................................
................................
....................
 
74
 
[IP_ADDRESS]
 
Lack of Efficacy (See Section 9.4)
 
................................
................................
..........................
 
74
 
[IP_ADDRESS]
 
Elevated Intraocular Pressure (See Section 9.5)
 
................................
................................
......
 
74
 
[IP_ADDRESS]
 
Deleterious Effects of the Study Drug
 
................................
................................
.....................
 
74
 
[IP_ADDRESS]
 
Lack of Compliance
 
................................
................................
................................
................
 
74
 
9.1.2
 
Study Termination
 
................................
................................
................................
...................
 
74
 
9.2
 
Do
se Modification
 
................................
................................
................................
...................
 
75
 
9.3
 
Dosing Interruptions
 
................................
................................
................................
................
 
75
 
9.4
 
Rescue Management
 
................................
................................
................................
................
 
75
 
9.4.1
 
Criteria for Starting Rescue Medication
 
................................
................................
..................
 
75
 
9.4.2
 
Management
 
................................
................................
................................
............................
 
76
 
Clinical Study Protocol:  CPN
-
301
 
Formosa Pharmaceuticals, Inc.
 
APP13007
 
 
 
Version 1.
3 
(Amendment 1)
 
CONFIDENTIAL
 
Page 
12
 
of 
89
 
9.5
 
Management of Increased IOP
 
................................
................................
................................
 
76
 
9.5.1
 
Criteria for Starting IOP
-
Lowering Medication
 
................................
................................
......
 
76
 
9.5.2
 
Management
 
................................
................................
................................
............................
 
77
 
 
STATISTICAL CONSIDERATIONS
 
................................
................................
....................
 
78
 
10.1
 
Statistical Analytical Plan
 
................................
................................
................................
.......
 
78
 
10.2
 
Analysis Populations
 
................................
................................
................................
...............
 
78
 
10.3
 
Statistical Methods
 
................................
................................
................................
..................
 
78
 
10.3.1
 
General Approach
 
................................
................................
................................
....................
 
78
 
10.3.2
 
Analysis of Efficacy
 
................................
................................
................................
................
 
78
 
[IP_ADDRESS]
 
Analyses of Primary Efficacy Endpoints:
 
................................
................................
...............
 
79
 
[IP_ADDRESS]
 
Analyses of Secondary Efficacy Endpoints:
 
................................
................................
...........
 
[ADDRESS_812131] IN THE NON
-
STUDY EYE
 
................................
................................
................................
...........................
 
89
 
 
Clinical Study Protocol:  CPN
-
301
 
Formosa Pharmaceuticals, Inc.
 
APP13007
 
 
 
Version 1.
3 
(Amendment 1)
 
CONFIDENTIAL
 
Page 
[ADDRESS_812132] OF TABLES
 
Table 1:
 
Schedule of Events
 
................................
................................
................................
..................
 
24
 
Table 2:
 
Risk Mitigation Plan
 
................................
................................
................................
................
 
34
 
Table 3:
 
Study Objectives and Endpoints
 
................................
................................
..............................
 
38
 
Table 4:
 
Prohibited Medications and Minimum Washout Periods
 
................................
........................
 
53
 
Table 5:
 
Definitions of AE Severity
 
................................
................................
................................
......
 
68
 
Table 6:
 
Guidelines for Determining the Relationship (if any) between an Adverse Event and the 
Ocular Surgical Procedure
 
................................
................................
................................
.......
 
68
 
Table 7:
 
Guidelines for Determining the Relationship (if any) between an Adverse Event and the 
Study
 
Drug
 
................................
................................
................................
..............................
 
[ADDRESS_812133] OF FIGURES
 
Figure 1:
 
Study Schematic
 
................................
................................
................................
......................
 
23
 
Clinical Study Protocol:  CPN
-
301
 
Formosa Pharmaceuticals, Inc.
 
APP13007
 
 
 
Version 1.
3 
(Amendment 1)
 
CONFIDENTIAL
 
Page 
[ADDRESS_812134]
 
ITT
 
Intent
-
to
-
Treat
 
IU/L
 
international units per liter
 
IWRS
 
Integrated Web Response System
 
kg
 
kilogram
 
LLOQ
 
Lower 
Limit of Quantification
 
LOCF
 
Last Observation Carried Forward
 
MedDRA
 
Medical Dictionary for Regulatory Activities
 
mg
 
milligram
 
mg/kg
 
milligrams per kilogram
 
mm
 
millimeter
 
mmHg
 
millimeters of mercury
 
NSAID
 
Nonsteroidal 
Anti
-
inflammatory Drug
 
OTC
 
Over the Counter
 
PDR
 
Proliferative Diabetic Retinopathy
 
PHI
 
Protected Health Information
 
PI
 
[INVESTIGATOR_612597]:  CPN
-
301
 
Formosa Pharmaceuticals, Inc.
 
APP13007
 
 
 
Version 1.
3 
(Amendment 1)
 
CONFIDENTIAL
 
Page 
[ADDRESS_812135] Operating Procedure
 
SRM
 
Study Reference Manual
 
S[LOCATION_003]R
 
S
erious 
and 
Unexpected S
uspected
 
Adverse Reaction
 
TEAE
 
Treatment
-
E
mergent Adverse Event
 
 
Clinical Study Protocol:  CPN
-
301
 
Formosa Pharmaceuticals, Inc.
 
APP13007
 
 
 
Version 1.
3 
(Amendment 1)
 
CONFIDENTIAL
 
Page 
16
 
of 
89
 
PROTOCOL SYNOPSIS
 
Protocol Synopsis
 
Sponsor:
  
Formosa Pharmaceuticals, Inc.
 
US Representative:  
 
Title of Study:
  
A Multicenter, Randomized, Double
-
Masked, Placebo
-
Controlled, Parallel
-
Group 
Study to Evaluate the Efficacy 
and Safety 
of APP13007 for the Treatment of Inflammation and Pain 
after Cataract Surgery
 
Protocol Number:
  
CPN
-
301
 
Phase:  
3
 
Active 
Ingredient:
  
 
Name [CONTACT_612675]
:  
APP13007 
 
 
Description of 
Investigational
 
Drug:
  
APP13007
 
Study Center(s):
 
 
~
26
 
in the [LOCATION_003]
 
Study Duration:  
~
 
[ADDRESS_812136]
-
operative day (POD) [ADDRESS_812137] surgery
 
in the study eye
.
 
Primary Efficacy Endpoints
 

 
The proportion of 
subject
s
 
with Anterior 
Chamber Cell (ACC) Count = 0 
[ACC G
rade = 
0]
 
at 
post
-
operative d
ay
 
8
  
 
(POD8),
 
maintained 
through POD15 
 

 
The proportion of 
subject
s
 
with Ocular Pain 
Grade = [ADDRESS_812138] surgery 
in the study eye
.
 
Secondary Efficacy Endpoints
 

 
Proporti
on of 
subject
s
 
with ACC count = 0 
[ACC
 
Grade = 0] 
at PODs 4, 8 and 15
 

 
Proportion of 
subject
s
 
with Ocular Pain Grade = 
0 at PODs 4, 8 and 15 
 

 
Proportion of 
subject
s
 
with Anterior chamber 
flare (ACF) Grade = 0 at POD8 maintained 
through POD15 
 

 
Proportion of 
subject
s
 
with ACF Grade = 0 at 
PODs 4, 8 and 15
 

 
Mean 
change
-
from
-
baseline
 
in ACC Grade at 
PODs 4, 8, and 15
 

 
Mean 
change
-
from
-
baseline
 
in Ocular Pain 
G
rade
 
at PODs 4, 8 and 15
 

 
Mean 
change
-
from
-
baseline
 
in ACF 
G
rade
 
on 
PODs 4, 8 and 15 
 

 
Number 
of 
subject
s
 
rescued on or prior to each 
visit and overall
 

 
Mean 
change
-
from
-
baseline
 
in best corrected 
visual acuity by [CONTACT_21173][INVESTIGATOR_612598] 
(ETDRS) chart at PODs 4, 8 and 15
 

Clinical Study Protocol:  CPN
-
301
 
Formosa Pharmaceuticals, Inc.
 
APP13007
 
 
 
Version 1.
3 
(Amendment 1)
 
CONFIDENTIAL
 
Page 
[ADDRESS_812139] surgery.
 
Safety Endpoints
 

 
Adverse events (AEs) 
 

 
Best corrected visual acuity by [CONTACT_21173][INVESTIGATOR_612599] f
ro
m baseline to each 
post
-
surgery visit
 

 
Slit
-
lamp biomicroscopy
 
o
 
Change
-
from
-
baseline in ocular signs to 
each post
-
surgery visit
 

 
Dilated indirect ophthalmoscopy
 
o
 
Change
-
from
-
baseline in ocular signs to 
Visit 6 (POD22)
 

 
Intraocular pressure (IOP) at each visit and 
change
-
from
-
baseline to Visit 6 
(
POD22
) 
measured with a Goldman
n applanation
 
tonometer
 
Study Design
 
& Summary of Visit Schedule
:
 
This Phase [ADDRESS_812140] 
surgery on Day 0 of the study and will be assessed the next day (POD1) after uncomplicated surgery for 
eligibility 
for
 
r
andomization to study treatment.
 
Subject
s
 
who experience postoperative inflammation on POD1 and who meet all other eligibility criteria 
will be randomized to one of two study treatments (either Treatment 1 or Treatment 2)
 
at 
a 1:1
 
ratio
:
  
 

 
Treatment 1:  
1 drop APP13007 twice daily (BID) (morning and evening) for 14 days 
instilled 
to 
the operated study eye
 

 
Treatment 2:  
1 drop matching vehicle placebo BID (morning and evening) for 14 days 
instilled 
to 
the operated study eye
 
 
Study Visits
 
and Procedures
 
Vis
it 1
:
 
Screening
.
 
Sign informed consent prior to the conduct of any study procedures or 
discontinuation of any medications related to this study. Screening will occur between [ADDRESS_812141] surgery. Review Inclusion and Exclusion criteri
a for eligibility. 
 
Day 0/Day of Surgery:
 
Subject
s
 
undergo routine cataract surgery via phacoemulsification and posterior 
chamber intraocular lens implantation according to the Investigator’s normal procedures. 
 
Visit 2:
 
POD1
 
will occur ~ [ADDRESS_812142] surgery. Review Inclusion and Exclusion criteria. 
Baseline pre
-
Randomization assessments (ocular inflammation, pain and safety 
parameters
). 
Randomization of eligible 
subject
s
. Instillation of first dose of study 
drug
 
in
 
the operated study eye in 
the clinic under the supervision of Investigator or designee. 
 
Visit 3:
 
POD4 (± 1 day). Ocular inflammation, pain and safety assessments.
 
Visit 4:
 
POD8
 
(± 1 day). Ocular inflammation, pain and safety assessments.
 
[Note: 
Subject
s
 
will be contact[CONTACT_463815]14 to remind them to stop study drug 
after
 
that day and to 
bring the study drug bottle and dosing diary to the clinic the next day.]
 
Visit 5:
 
POD15 (+ 1 d
ay). Ocular inflammation, pain and safety assessments.
 
Urine pregnancy test.
 
Visit 6:
 
POD22 (± 2 days). Ocular inflammation, pain and safety assessments. Final visit. 
 
A
 
detailed
 
summary of study events is pro
vided in 
Table 
1
 
(Schedule of Events) and a study design 
schematic is provided in
 
Figure 1
 
(Study S
chematics). 
 
Clinical Study Protocol:  CPN
-
301
 
Formosa Pharmaceuticals, Inc.
 
APP13007
 
 
 
Version 1.
3 
(Amendment 1)
 
CONFIDENTIAL
 
Page 
[ADDRESS_812143], Dose and Mode of Administration:  
 
Study Drugs (APP13007
 
or matching vehicle placebo) will be supplied in an eye drop bottle. The 
formulations are preserved with benzalkonium chloride filled in a multi
-
dose opaque low density 
polyethylene (LDPE) 5 mL round dropper bottle with a LDPE tip and tightly closed with 
a 
pi[INVESTIGATOR_612600] (HDPE) cap. The bottle will be labelled in accordance with FDA regulations for an 
investigational product. 
 
One bottle of study drug will be dispensed to each 
randomized 
subject
 
in the trial. Study drug will be 
administered
 
twice daily (morning and evening) by [CONTACT_612633]. If the 
subject
 
misses his/her eye during instillation, then a second drop 
will be instilled and this will be documented in the dosing 
diary.
 
Randomization:  
Subject
s
 
who meet all eligibility criteria on POD1 will be randomized to one of the 
two study treatments 
at
 
a 1:1 ratio (
APP13007
:pl
acebo). 
 
Number of 
Subject
s
:  
 
A sufficient number of 
subject
s
 
will be screened to allow approximately [ADDRESS_812144]
s
 
(185 on 
APP13007
 
and 185 on placebo) to be randomized
.
 
 
Inclusion Criteria:
 
To be eligible, a participant must meet the following criteria:
 
At the Screening Visit (Visit 1):
 
1.
 
Provide signed and 
dated informed consent
 
2.
 
Age 
≥ [ADDRESS_812145] been permanently sterilized or are postmenopausal. Postmenopausal is defined as 
amenorrhea for a 
minimum of 12 months (without an alternative medical cause). 
Note:
 
Pregnant 
women or nursing 
(breast
-
fee
ding) 
mothers are excluded from the study. 
 
4.
 
W
omen
-
of
-
childbearing
-
potential 
are
 
eligible for enrollment if they have a negative 
urine 
pregnancy test on POD1 prior to Randomization
 
and they agree to abstain from sexual activity or 
use a highly effective con
traceptive such as occlusive cap (diaphragm or cervical/vault cap) plus 
spermicidal agent (foam/gel/film/cream/suppository), oral contraceptive, injectable progesterone, 
implant of etonogestrel or levonorgestrel, estrogenic vaginal ring, percutaneous contr
aceptive 
patches, or intrauterine device from POD1 to Visit 6 (POD22)
.
 
5.
 
Expected to undergo unilateral uncomplicated cataract extraction via phacoemulsification and 
posterior chamber intraocular lens implantation in one eye (designated the ‘Study Eye’)
 
6.
 
Have
 
a pin
-
hole corrected visual acuity without other correction of 
≤ 1.3 logarithm of the minimum 
angle of resolution (logMAR) in the study eye to be operated and contralateral eye as measured 
using an Early Treatment Diabetic Retinopathy Study (ETDRS) chart 
at Visit 1. 
Subject
s
 
who are 
unable to read the lines in an ETDRS chart because of the density of the cataract in the study eye 
may be enrolled if, in the opi[INVESTIGATOR_689], there is no other significant ocular pathology 
that would account for th
e low visual acuity.
 
7.
 
Willing and able to comply with study requirements and visit schedule; Able to either self
-
administer study medication or have someone available (e.g., spouse, caregiver, etc.) who can 
administer study medication according to the study
 
schedule and instructions
.
 
 
Additional Inclusion Criteria on Postoperative Day (POD) 1/Day of Randomization (Visit 2):
 
8.
 
Have undergone unilateral cataract extraction via phacoemulsification and posterior chamber 
intraocular lens implantation in the 
study eye without any additional procedures or complications 
that would
, in the opi[INVESTIGATOR_689], interfere with study procedures or confound study 
objectives
.
 
Clinical Study Protocol:  CPN
-
301
 
Formosa Pharmaceuticals, Inc.
 
APP13007
 
 
 
Version 1.
3 
(Amendment 1)
 
CONFIDENTIAL
 
Page 
[ADDRESS_812146] 
≥ 10 cells in the anterior chamber (excluding red blood and pi[INVESTIGATOR_482429])
 
11.
 
Have an IOP 
≤ 30 mmHg. 
Note: 
I
f the IOP is elevated 
post
-
surgery, 
the investigator may 
use 
non
-
prostaglandin based 
IOP
-
lowering medication(s) at their discretion
 
on the day of surgery
 
(Day 0) 
only
. The IOP 
will
 
be measured and recorded
 
on POD1
 
to determine eligibility for Randomization.
 
 
Exclusion Criteria:
 
Participants will be excluded if they meet any of the following criteria: 
 
1.
 
Have a known sensitivity or allergy to clobetasol propi[INVESTIGATOR_16847], corticosteroids, or any of the study 
medication’s components including benzalkonium chloride and soybean lecithin or an
y routine 
medication required during cataract surgery or for the conduct of study procedures
 
2.
 
Have an ACC 
count 
> 0 or any evidence of intraocular inflammation (e.g., flare) in either eye at the 
Screening visit 
 
3.
 
Have a Grade > [ADDRESS_812147] active or chronic/recurrent ocular or systemi
c disease that is uncontrolled and 
could
 
affect 
wound healing and/or resolution of inflammation after cataract surgery
 
6.
 
Suspected or known malignancy or be currently receiving antineoplastic therapy. Note: 
subject
s
 
with basal cell carcinoma will not be excl
uded unless the Investigator believes that the condition 
has the potential to interfere with study procedures or analysis of results.
 
7.
 
Are using certain medications, namely:
 
i.
 
Subject
s
 
receiving 
therapy
 
for macular 
degeneration 
(in either eye) 
with Eylea
®
 
(af
libercept), 
Avastin
®
 
(bevacizumab), Lucentis
®
 
(ranibizumab)
, 
Beovu
®
 
(brolucizumab
-
dbll) 
or Visudyne
®
 
(verteporfin) are excluded
.
 
ii.
 
PROKERA (preserved amniotic membrane) is excluded
 
from 1 year prior to the Screening 
visit to the end of the study
.
 
iii.
 
Anti
-
inflammatory agents, analgesics (including opi[INVESTIGATOR_2438], narcotics, nonsteroidal anti
-
inflammatory drugs (NSAIDs), aspi[INVESTIGATOR_248], acetaminophen and other pain medications) or 
immune
-
modulating agents systemically or in either eye from the beginning of the ‘Washo
ut’ 
period in the 
“
List 
of Prohibited Medications
”
 
until after the POD15 assessments
, 
but
 
preferably until after the POD22 assessments
. 
Note: 
(i)
 
acetaminophen is permitted on the day 
of surgery
; (ii) immunizations/vaccinations are permitted before and dur
ing the study
.
 
iv.
 
Use of any of the prohibited medications 
in the 
“
List of Prohibited
 
Medications
”
 
within a time 
period prior to surgery that is less than the minimum ‘washout’ period noted in the table. 
NOTE: (i) These medications may not be used from the beginning of the ‘Washout’ period in 
“
List of Prohibited Medications
”
 
until after the POD15 assess
ments
, but
 
preferably 
until 
after the POD22 assessments
; (ii) Medications for 
anesthesia
 
related to cataract surgery
, 
ocular
 
pain control and 
non
-
prostaglandin
-
based therapy for the treatment of raised 
intraocular pressure (IOP)
 
are allowed on the day of surgery only
.
 
v.
 
Non
-
approved drugs or investigational products 
other 
than 
the study drug
 
in this study 
are 
prohibited from [ADDRESS_812148]
 
has been released from the 
study.
 
Clinical Study Protocol:  CPN
-
301
 
Formosa Pharmaceuticals, Inc.
 
APP13007
 
 
 
Version 1.
3 
(Amendment 1)
 
CONFIDENTIAL
 
Page 
20
 
of 
89
 
Protocol Synopsis
 
Medication
 
Minimum ‘Washout
’ 
Period Prior to Day [ADDRESS_812149] cell stabilizers
 
2 days
 
Ocular antihistamines
 
2 days
 
Ocular and nasal decongestants
 
2 days
 
All eye drops (except antibiotic eye drops considered to be part of 
pre
-
cataract surgery standard
-
of
-
care). Note: Antibiotics with anti
-
inflammatory activity and Besifloxacin Ophthalmic suspension are not 
permitted. Note: (i) Artificial tears are allowed, but should not be used 
within 10 minutes of study procedures or medi
cation dosing; (ii) specific 
restrictions for ocular products are listed below.
 
2 days
 
Topi[INVESTIGATOR_243874] 
 
14 days
 
Topi[INVESTIGATOR_409464]
 
7 days
 
Topi[INVESTIGATOR_612601]
 
7 days
 
Systemic anti
-
inflammatory agents including acetaminophen, NSAIDS, 
acetylsalicylic acid (aspi[INVESTIGATOR_248]), and Lifitegrast. 
 
Note: (i) Use of acetylsalicylic acid for cardiovascular prophylaxis 
(i.e.,
 
81
 
mg dose QD) is allowed if dosage has been stable for at leas
t 
30
 
days prior to surgery and will remain stable for the duration of the 
study (ii) Acetaminophen may be administered as needed pre
-
 
and post
-
operatively on the day of surgery
, 
(iii) 
Over
-
the
-
Counter preparations 
such as Fish Oils, Turmeric and Ginseng th
at may have mild anti
-
inflammatory effects are allowed
.
 
7 days
 
Topi[INVESTIGATOR_612602] (use of 
topi[INVESTIGATOR_2855] 0.1% hydrocortisone dermal preparations for less than 3 days 
over a small area of skin [~2 inches x ~2 inches] a
re allowed).
 
14 days
 
Systemic (oral, injectable), inhaled and/or nasal corticosteroids
 
21 days
 
Systemic analgesics/pain relievers such as gabapentin, pregabalin, 
opi[INVESTIGATOR_612595]: Marijuana/CBD
-
containing products have the same washout 
restrictions a
s
 
“Systemic Analgesics” 
because they can affect pain 
perception
 
14 days
 
Medications for benign prostatic hypertrophy (BPH) (e.g., finasteride
, 
α
-
1
 
adrenergic receptor antagonists
) 
are allowed based on the judgment 
of the 
investigator
. 
Note:
 
Investigators should consider 
the potential risk 
of intraoperative floppy iris syndrome in
 
subjects who are taking or have 
taken 
α
-
1 adrenergic receptor antagonists (eg.
 
tamsulosin, silodosin, 
alfuzosin).
 
Stable dose for 
28 days
 
Topi[INVESTIGATOR_612603]
 
60 days
 
Periocular injection of corticosteroid
 
28 days
 
Intraocular treatment with corticosteroid 
-
 
dexamethasone drug delivery 
system
 
90 days after 
implantation
 
Intraocular treatment with corticosteroid 
–
 
fluocinolone acetonide drug 
delivery system
 
48 months after 
implantation
 
Clinical Study Protocol:  CPN
-
301
 
Formosa Pharmaceuticals, Inc.
 
APP13007
 
 
 
Version 1.
3 
(Amendment 1)
 
CONFIDENTIAL
 
Page 
21
 
of 
89
 
Protocol Synopsis
 
Stable doses of anticholinergics and antidepressants are allowed. 
Alterations of the dose of anticholinergics and antidepres
sants (other than 
for prn use as a sleep aid) may be allowed following consultation with 
the Study Medical Monitor. Anticholinergic eye drops used to dilate the 
eye are allowed. Systemic anticholinergic drugs are allowed on the day 
of surgery. 
 
 
Note 1
 
For anti
-
depressants used to treat depression: (i) Medication must not be 
washed
-
out for the purpose of enrollment in the study; (ii) Stable doses 
of anti
-
depressants are allowed; (iii) When the dose of an anti
-
depressant 
has been altered, the subject need
s to be on the stable altered dose for at 
least 90 days prior to the day of surgery (Day 0).
 
 
Note 2
 
For anti
-
depressants used to treat pain: (i
) The instructions provided for 
systemic analgesics/pain relievers apply, viz. at least a 14 day washout of 
the medication is required prior to the day of surgery (Day 0) continuing 
until the POD15 assessments have been completed.
 
See Note [ADDRESS_812150] an IOP < 5 mmHg or > 22 mmHg in 
either eye 
or a difference of > [ADDRESS_812151] active or a history of chronic or recurrent inflammatory eye disease (e.g., iritis, scleritis, 
uveitis, iridocyclitis, rubeosis iridis) in the study eye
 
13.
 
Have evidence of acute external ocular infections (bacterial,
 
viral and/or fungal infections including 
vaccinia, varicella and other viral diseases of the cornea and conjunctiva); tuberculosis of the eye; 
intraocular infections, active chalazion, or uncontrolled severe blepharitis in the study eye
 
14.
 
Have corneal 
dystr
ophies, 
including corneal guttae and Fuchs’ dystrophy,
 
or dysthyroid 
ophthalmopathy in the
 
study eye
 
15.
 
Have uncontrolled and clinically significant dry eye syndrome in the study eye (mild dry eye with 
the use of artificial tears is allowed)
 
16.
 
Have proliferativ
e diabetic retinopathy, significantly compromised macular function; significant 
macular disease; have clinically
-
significant macular edema or a history of cystoid macular edema in 
the study eye; have cup:disc ratio > 0.[ADDRESS_812152] had corneal or retinal 
surgery (laser or incisional) in the study eye within [ADDRESS_812153] laser or incisional surgery during the study period in the study 
eye (other than cataract surgery)
 
18.
 
Have ocular surgery planned, scheduled or performe
d on the contralateral eye within the [ADDRESS_812154]
-
surgical outcome (including, but not limited to intraocular inflammation, IOP or the normal 
healing process)
 
Clinical Study Protocol:  CPN
-
301
 
Formosa Pharmaceuticals, Inc.
 
APP13007
 
 
 
Version 1.
3 
(Amendment 1)
 
CONFIDENTIAL
 
Page 
[ADDRESS_812155] surgery or for 
the remaind
er of the study period in either eye
 
21.
 
Require use of non
-
diagnostic topi[INVESTIGATOR_612604]: mydriatics, anesthetics, antiseptics, 
balanced salt solutio
n, viscoelastics, osmotic agents (e.g., Muro 128), prophylactic antibiotics, non
-
prostaglandin analog IOP
-
lowering agents for IOP increases 
on the day of
 
cataract surgery, lid 
scrubs for mild blepharitis, or artificial tears for the management of mild dry 
eye. 
 
22.
 
In the opi[INVESTIGATOR_871], have the potential for ocular hemorrhage in the study eye that may 
interfere with evaluation of post
-
surgery inflammation
 
23.
 
Have a planned use of or use of femtosecond laser or any other ophthalmic surgical procedure
 
(e.g.,
 
vitrectomy, relaxing incisions, iridectomy, conjunctival excisions, use of iris hooks or other 
iris dilators, etc.) in addition to the cataract extraction procedure via phacoemulsification and PCIOL 
implantation in the study eye
 
24.
 
Have a planned use 
of or use anterior capsule staining for capsulorhexis (i.e., trypan blue) during 
cataract surgery
 
25.
 
Have planned to participate in another clinical trial during the duration of this study
 
26.
 
Have participated in another clinical study or received any investigat
ional product within the past 
[ADDRESS_812156] surgery is for the eye that was the ‘non
-
study’ eye in that study. 
 
27.
 
Have any other condition that
 
the Investigator determines should exclude the subject from the trial. 
 
28.
 
Are an employee of the clinical site that is directly involved in the management, administration, or 
support of this study or are an immediate family member of the same
.
 
Statistical Methods:
 
All analysis variables will be summarized descriptively by [CONTACT_1570]. Summary statistics for 
continuous measures will include the number of subjects (n), mean, standard deviation, median, and 
range. Categorical measures will be s
ummarized by [CONTACT_202352]. 
 
Analyses of Primary Efficacy Endpoints:
 
The primary efficacy analyses to compare APP13007
 
against placebo will be conducted on the Intent
-
To
-
Treat (ITT) population using the Pearson Chi
-
square statistic. Fixed sequence testing will be 
employed to maintain the 2
-
sided alpha = 0.05. The primary analyses will first test the difference in the 
prop
ortion of subjects with ACC count = 0 (Grade = 0) at POD8 (Visit 4) maintained through POD15 
(Visit 5)
 
between treatment groups. If the test is statistically significant at the 2
-
sided alpha = 0.05 level 
in favor of APP13007, the difference in the proporti
on of subjects with Ocular Pain Grade = 0 at POD4 
(Visit 3) maintained through POD15 (Visit 5) between treatment groups will be tested at the two
-
sided 
alpha = 0.05 level. 
 
Analyses of Secondary Efficacy Endpoints:
 
Mean 
change
-
from
-
baseline in ACC Grade, O
cular Pain Grade, ACF Grade and visual acuity at PODs 4, 
8 and 15 will be analyzed using an analysis of covariance (ANCOVA). The ANCOVA model will 
include treatment as 
a 
fixed effect and baseline as a covariate. The rest of secondary efficacy endpoints 
wil
l be analyzed using the same method described for the primary efficacy endpoints. 
Rescued subjects 
will be considered to be treatment failures.
 
Safety Analysis:
 
The safety analysi
s will summarize ocular treatment emergent AEs (TEAEs) in the study eye and o
cular 
AEs for the non
-
study eye. Ocular and non
-
ocular TEAEs will be summarized similarly. 
 
 
The other safety endpoints will be summarized as discussed in the Statistical Considerations section of 
the protocol.
 
Clinical Study Protocol:  CPN
-
301
 
Formosa Pharmaceuticals, Inc.
 
APP13007
 
 
 
Version 1.
3 
(Amendment 1)
 
CONFIDENTIAL
 
Page 
23
 
of 
89
 
 
STUDY DESIGN
 
Figure 
1
:
 
Study Schematic
 
 
 
 

Clinical Study Protocol:  CPN
-
301
 
Formosa Pharmaceuticals, Inc.
 
APP13007
 
 
 
Version 1.2
 
CONFIDENTIAL
 
Page 
24
 
of 
89
 
Table 
1
:
 
Schedule of Events
 
PROCEDURE/ASSESSMENTS 
1 
 
Visit 1
 
Screening 
 
(Day 
-
28 to 
-
1)
 
Surgery 
2
 
Day 0
 
Visit 2
 
POD1 
3
 
Visit 3 
POD4
 
(±1 Day)
 
Visit 4
 
POD8
 
(±1 Day)
 
Contact
 
[CONTACT_234945]14
 
Visit 5
 
POD15
 
(+1 Day) 
4
 
Visit 6
 
POD22
 
(±2 Days) 
5
 
ICF, Demography, Medical History 
 
X
 
 
 
 
 
 
 
 
Determine Eligibility, Review Inclusion/Exclusion Criteria 
 
X
 
 
X
 
 
 
 
 
 
U
rine pregnancy test 
only 
for women of child
-
bearing potential
 
 
 
 
X
 
 
 
 
X
 
 
Ocular Symptoms Assessment 
[ADDRESS_812157] Ophthalmoscopy (dilated)
 
X
 
 
 
 
 
 
 
X
 
lOP (Goldmann applanation tonometry) 
8
 
X
 
 
X
 
X
 
X
 
 
X
 
X
 
Randomization
 
 
 
X
 
 
 
 
 
 
Dispense Study Drug 
 
 
 
X
 
 
 
 
 
 
Study Drug Dosing BID for 14 days (POD1 to POD14) 
[ADDRESS_812158] (with instructions for completion)
 
 
 
X
 
X
 
X
 
 
 
 
Contact 
[CONTACT_27720]
 
[ADDRESS_812159] and Check Diary Cards for Accuracy and Compliance 
 
 
 
 
X
 
X
 
 
X
 
 
AEs 
7
 
and Concomitant Medications 
1
1
 
X
 
X 
1
2
 
X
 
X
 
X
 
X 
1
3
 
X
 
X
 
1
 
Ophthalmic assessments will be performed in the study eye only at Visits 2
-
5
;
 
and performed on both eyes at Visit 1 (Screening) and at Visit 6 (POD22)
 
or at 
subject
 
E
arly 
T
ermination
/Withdrawal
.
 
[ADDRESS_812160] occur between one to 28 days after Screening, preferably in the morning. If, due to unexpected events, surgery i
s postponed and would occur > [ADDRESS_812161] surgeon should be reviewed to rule out proh
ibited medications (
Section 
5.4.2
).
 
3
 
Visit 2 (POD1
) should be scheduled between 18 to 34 hours following conclusion of surgery on Day 0. All assessments done on POD1 are done 
prior to Randomization to ensure eligibility. 
Note: Women
-
of
-
childbearing
-
potential are eligible for enrollment if they have a nega
tive urine pregnancy test on POD1 prior to Randomization
 
and they agree to abstinence from sexual activity or use of 
highly 
effective 
method of 
contraception
.
 
4
 
Visit 5 (POD15) occurs on the day after the 
subject
 
completes the
 
study drug administration for
 
[ADDRESS_812162].
 
5
 
Visit 6 (POD22) is the last visit for 
subject
s
 
who complete the study. 
Subject
s
 
who are withdrawn early should have the Visit [ADDRESS_812163] AEs and how to determine attributability (relatedness) of AE to study procedures
 
(including 
cataract surgery) or study drug.
 
7
 
Ocular inflammation 
assessment using ACC count, 
anterior chamber 
flare grade, bulbar conjunctival injection, sclera 
-
 
ciliary flush and corneal edema.
 
8
 
IOP should (but not required) be assessed at each visit within ± [ADDRESS_812164]
s
 
who are rescued will not 
continue to instill study drug or receive further diary car
ds but will remain in the study to complete 
the procedures/assessments 
through 
Visit 6 (POD22). 
 
[ADDRESS_812165]
’s
 
preferred method
 
on POD14
 
to remind him/her not to instill study drug on POD15 and to bring the bottle of study drug and the dosing diary back to the s
ite at 
the POD15 visit.
 
1
1
 
Concomitant medications used for rescue should be reported in the eCRF.
 
1
2
 
AEs and 
Concomitant Medicati
ons
 
should only be recorded on Day 0 if they result in disqualification (i.e., screen failure) of the 
subject
; otherwise, the AEs and Con
comitant 
Med
ication
s applicable to Day [ADDRESS_812166]
 
returns for Visit 2 (POD1).
 
[ADDRESS_812167] be recorded in the source documents. Further assessment of any reported AEs m
ay require an Unscheduled Visit on POD14 if medically significant 
or they may be assessed, as appropriate, during Visit 5 (POD15)
.
 
Clinical Study Protocol:  CPN
-
301
 
Formosa Pharmaceuticals, Inc.
 
APP13007
 
 
Version 1.
3 
(Amendment 1)
 
CONFIDENTIAL
 
Page 
[ADDRESS_812168] by [CONTACT_612634], proteins that inhibit phospholipase A2, an enzyme 
that releases arachidonic acid 
from membrane phospholipi[INVESTIGATOR_805]. By [CONTACT_612635] A2, lipocortins control the 
biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.
 
CP is an analog of prednisolone with a very high d
egree of activity at the glucocorticoid receptor 
and only slight degree of mineralocorticoid activity
 
(
Clobex® 2018
)
. I
t is reported to be the most 
potent corticosteroid in terms of binding affini
ty to the glucocorticoid receptor and resulting 
pharmacological e
ffects
 
(
Olsen 1986
)
, 
(
Jacob 2006
)
. C
P 
has been used in dermal applications 
including ointments, creams and shampoos, where its efficacy and safety has
 
been 
well
-
establishe
d
 
(
Clobex® 2018
)
; 
(
Temovate® 2000
)
; 
(
Olsen 1986
)
; 
(
Hengge 2006
)
; 
(
Feldman 2009
)
.
 
1.2.[ADDRESS_812169] removal and 
intraocular lens placement regularly leads to some degree of inflammation. The cellular damage 
on the surface of the cornea activates an inflammatory process that manifests initially as 
hyperemia, corneal edema, and incre
ased anterior chamber cells and flare. More serious 
complications such as corneal edema, increases in intraocular pressure (IOP), cystoid macular 
edema (CME), and posterior capsule opacification may result if the inflammatory process is not 
managed appropr
iate
ly 
(
Tennant 1978
)
 
(
Apple 1992
)
. F
or this purpose, a post
-
cataract surgery 
regimen of anti
-
inflammatory agents (such as corticosteroi
ds) is typi[INVESTIGATOR_612605], pain and discomfort and reduces the risk of further complications. When 
administered at the time of surgery and during the immediate postoperative period, 

Clinical Study Protocol:  CPN
-
301
 
Formosa Pharmaceuticals, Inc.
 
APP13007
 
 
Version 1.
3 
(Amendment 1)
 
CONFIDENTIAL
 
Page 
26
 
of 
89
 
corticosteroids can reverse the clinica
l and non
-
clinical manifestations
 
of inflammation 
(
Leopold 
1985
)
 
(
Aptel 2017
)
.
 
1.2.3
 
Rationale for Development of 
APP13007
 
Topi[INVESTIGATOR_612606] a well
-
established therapy for the treatment of 
inflammation and pain after ocular surgery
 
(
Aptel 2017
)
, 
and several marketed products are 
currently available th
at contain active ingredients such as dexamethasone, prednisolone, 
loteprednol etabonate and difluprednate. 
 
CP has been used for over 30 years in the US, Europe and Japan to treat the inflammatory and 
pruritic manifestations of corticosteroid responsive d
ermatoses such as psoriasis, eczema and 
atopic dermatitis. CP has not been previously developed for ophthalmic use, presumably due to 
its lack of aqueous solubility. Nevertheless, given its increased potency, an aqueous ophthalmic 
formulation of CP has the
 
potential to produce rapid clearance of anterior chamber cells (ACC), 
return of visual acuity and relief of pain after ocular surgery, surpassing the effectiveness of 
corticosteroids currently on the market. 
 
APP13007 is an ophthalmic nanosuspension that 
is prepared by [CONTACT_612636] a 
mixture of excipi[INVESTIGATOR_840]. The proprietary nanomilling technology allows CP to be formulated as an 
aqueous suspension. This suspension of CP nanoparticles in APP13007 is designed to promote 
efficient penetration o
f CP into the eye upon ocular surface instillation, thus delivering 
therapeutically relevant concentrations of CP to the target tissues within the eye.
 
1.[ADDRESS_812170] bee
n 
conducted with various formulations of APP13007, and these are summarized in the APP13007 
Investigator Brochure.
 
1.3.1
 
P
rimary 
P
harmacology
 
 
 
 
 
 
1.3.2
 
P
harmacokinetics
 
 

Clinical Study Protocol:  CPN
-
301
 
Formosa Pharmaceuticals, Inc.
 
APP13007
 
 
Version 1.
3 
(Amendment 1)
 
CONFIDENTIAL
 
Page 
27
 
of 
89
 
 
 
 
 
1.3.3
 
T
oxicology
 
Data from non
-
GLP and 14
-
day and 28
-
day Good Laboratory Practice (GLP) toxicity studies of 
APP13007 are summarized in the APP13007 Investigator Brochure. 
 
 
n 
 
) 
 
 
 
T
he toxicology studies suggest that 
potential systemic effects in human subjects with ocular instillations of APP13007 are those 
typi[INVESTIGATOR_612607]
l CP products, 
such as Temovate
®
 
and Clobex
®
 
(
Temovate® 2000
)
; 
(
Clobex® 2018
)
.
 
The data from repeat dose toxicology studies d
id
 
not identify any unacceptable risk for human 
subjects. 
 
1.[ADDRESS_812171] and results
 
are summarized in the APP13007 Investigator Brochure.
 
1.4.1
 
CPN
-
201: A 
Phase [ADDRESS_812172] Surgery 
 
T
his was a multi
-
center, randomized, double
-
masked, placebo
-
controlled, parallel
-
group Phase 2 
study conducted in two parts (Parts A and B) to evaluate two APP13007 dose streng
ths and two 
dosing frequencies
 
in subjects 
who had 
undergo
ne
 
routine cataract surgery and lens implantation. 
On Post
-
Operative Day 1 (POD1), subjects who met eligibility criteria were enrolled in the study 
and randomized
 
 
to 
one of the 
study treatment
s
 
ins
tilled in the operated study eye
: Treatment 1 or 
2 in Part A
 
(1:1 ratio)
; T
r
eatment 3, 4
,
 
5, or 6 in Part B
 
(1:1:1:1 ratio). A total of 45 subjects were 
randomized in Part A and 87 subjects randomized in Part B.
 

Clinical Study Protocol:  CPN
-
301
 
Formosa Pharmaceuticals, Inc.
 
APP13007
 
 
Version 1.
3 
(Amendment 1)
 
CONFIDENTIAL
 
Page 
28
 
of 
89
 

 
Treatment 1:  1 drop 0.05% APP13007 BID for 
21 days 
 

 
Treatment 2:  1 drop 
0.05% 
matching vehicle placebo BID for 21 days 
 

 
Treatment 3:  1 drop 0.05% APP13007 BID for 3 days followed by 1 drop 0.05% APP13007 
QD for 11 days 
 

 
Treatment 4:  1 drop 0.05% matching vehicle placebo BID for 3 days followed b
y 1 drop 
0.05% matching vehicle placebo QD for 11 days 
 

 
Treatment 5:  1 drop 0.1% APP13007 BID for 3 days followed by 1 drop 0.1% APP13007 
QD for 11 days  
 

 
Treatment 6:  1 drop 0.1% matching vehicle placebo BID for 3 days followed by 1 drop 0.1% 
matching vehicle placebo QD for 11 days 
 
[IP_ADDRESS]
 
Safety Results  
 
The 
0.05% 
APP13007 and 
0.1% 
APP13007 dosing regimens were well
-
tolerated with a safety 
profile similar to th
e matching placebo vehicles. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
[IP_ADDRESS]
 
Efficacy Results
 
 
-
 
 
 
 
 

Clinical Study Protocol:  CPN
-
301
 
Formosa Pharmaceuticals, Inc.
 
APP13007
 
 
Version 1.
3 
(Amendment 1)
 
CONFIDENTIAL
 
Page 
29
 
of 
89
 
 
 
 
 
 
 
 
 
 
 
 
 
[IP_ADDRESS]
 
Conclusion 
 
The safety and efficacy results from study CPN
-
201 support the further clinica
l evaluation of 
0.05% APP13007 
BID for the treatment of 
i
nflammation and pain following ocular surgery.
 
1.4.2
 
CPN
-
102: A 
Phase 1 Pharmacokinetic Study in Healthy Subjects
 
CPN
-
102
 
was 
an open
-
label, sequential dosing
, Phase 1 
pharmacokinetic (
PK
)
 
study 
to evaluate 
the 
systemic exposure 
of CP 
following ocular instillation of 0.05% APP13007 in healthy 
subjects. 
 
 
  
 
 
 
 
 
 
 
  
 
 
 
 
 
 
[IP_ADDRESS]
 
Safety Results
 
The 0.05% APP13007 drops were well
-
tolerated. There were 
no 
AEs related to the study drug.
 
[IP_ADDRESS]
 
Pharmacokine
tic Results 
 
 
 
 

Clinical Study Protocol:  CPN
-
301
 
Formosa Pharmaceuticals, Inc.
 
APP13007
 
 
Version 1.
3 
(Amendment 1)
 
CONFIDENTIAL
 
Page 
30
 
of 
89
 
 
[IP_ADDRESS]
 
Conclusion
 
 
 
 
 
 
 
1.5
 
Risk/Benefit Assessment
 
1.5.1
 
P
otential 
R
isks
 
[IP_ADDRESS]
 
Potential Risks Anticipated B
ased on Results from 
the GLP Rab
b
it Toxicology 
Studies with APP13007 
 
 
 
 
 
 
 
[IP_ADDRESS]
 
Potential Risks Anticipated Based on Results from the 
Human 
Studies with 
APP13007
 
As summarized in the APP13007 Investigator Brochure and in 
Section 
[IP_ADDRESS]
 
and 
Section 
[IP_ADDRESS]
, 
0.05% APP13007 
BID 
for 21 days 
wa
s well
-
tolerated
. 
 
 
 
 
 
 
 
 
. 
 
 
 
 
 
 
 
 
the 
systemic 
tolerability 
profile 
after ocular instillation of 0.05% APP13007 BID for 14 days 
is 
expected
 
to be considerably better than
 
that
 
for dermal 
CP 
products
 
summarized below
. 
 

Clinical Study Protocol:  CPN
-
301
 
Formosa Pharmaceuticals, Inc.
 
APP13007
 
 
Version 1.
3 
(Amendment 1)
 
CONFIDENTIAL
 
Page 
31
 
of 
89
 
[IP_ADDRESS]
 
Potential Risks Associated with the Use of CP in the Treatment of 
Corticosteroid
-
Responsive Dermatoses
 
There is extensive experience with CP in the treatment of inflammatory and pruritic 
manifestations of corticosteroid
-
responsive dermatoses, where its saf
ety and anti
-
inflammatory 
profile has been well defined
 
(
Olsen 1986
)
; 
(
Hengge 2006
)
; 
(
Feldman 2009
)
. 
The
se risks are 
summarized in the APP13007 Investigator’s Brochure.
 
Potential 
n
on
-
o
cular 
r
is
ks
 
include
:
 

 
Hypothalamic
-
Pi[INVESTIGATOR_2117]
-
Adrenal (HPA) Axis Suppression
.
 
Recovery of HPA
 
axis function is 
generally prompt upon discontinuation of topi[INVESTIGATOR_11930]. 
 

 
Cushing's syndrome, hyperglycemia, and unmasking of latent diabetes mellitus
. 
Use of more 
than one corticosteroid
-
containing product at the same time may increase the 
total systemic 
corticosteroid exposure.
 

 
Skin:  Allergic contact [CONTACT_612637]. 
 

 
Pregnancy and Nursing 
(
B
reast
-
feeding) 
Mothers: 
 
o
 
C
orticosteroids 
are
 
teratogenic in laboratory animals when administered systemically at 
relatively low dosage levels (Pr
egnancy Category C). When administered 
subcutaneously, CP was a significant teratogen in both the rabbit and mouse. 
Females of 
child
-
bearing potential are eligible to participate in this study 
only
 
if they have a negative 
urine pregnancy test on POD1 pre
-
r
andomization and they agree to use 
highly 
effective 
contraception from POD1 to POD22. Note: Pregnant and/or 
nursing 
(breast
-
feeding)
 
mothers are excluded from participation in this study. 
 
o
 
Systemically administered corticosteroids appear in human milk and 
could suppress 
growth, interfere with endogenous corticosteroid production, or cause other untoward 
effects. It is not known whether ocular administration of APP13007 could result in 
sufficient systemic absorption of CP to produce detectable concentrations
 
in human milk.
 
Potential ocular risks are summarized below.
 
[IP_ADDRESS]
 
Potential Class
-
Related Ocular Risks Associated with Corticosteroid Therapi[INVESTIGATOR_612608]13007, 
 is a po
tent corticosteroid so it has the following 
anticipated ocular risks associated with the corticosteroid class:
 

 
Intraocular pressure (IOP) increase 
–
 
prolonged use may result in glaucoma with damage to 
the optic nerve, defects in visual acuity and field of 
vision. 
 

 
Cataracts 
–
 
Prolonged use 
 may result in posterior subcapsular cataract 
formation in the non
-
operated eye. 
 

Clinical Study Protocol:  CPN
-
301
 
Formosa Pharmaceuticals, Inc.
 
APP13007
 
 
Version 1.
3 
(Amendment 1)
 
CONFIDENTIAL
 
Page 
32
 
of 
89
 

 
Delayed healing 
–
 
Use 
 after cataract surgery may delay healing and increase 
the incidence of bleb formation. In thos
e diseases causing thinning of the cornea or sclera, 
perforations have been known to occur with the use of topi[INVESTIGATOR_11930]. 
 

 
Risk of Infection
 
o
 
Bacterial infections 
–
 
Prolonged use 
 may suppress the host immune 
response and thus increase 
the hazard of secondary ocular infections. In acute purulent 
conditions, corticosteroids may mask infection or enhance existing infection.
 
o
 
Viral infections 
–
 
Use of ocular corticosteroids may prolong the course and may 
exacerbate the severity of many viral
 
infections of the eye (including herpes simplex). 
 
o
 
Fungal Infections 
–
 
Fungal infections of the cornea are particularly prone to develop 
coincidentally with long
-
term local corticosteroid application. Fungus invasion must be 
considered in any persistent c
orneal ulceration while a 
subject
 
is participating in this 
clinical trial.
 
In clinical studies evaluating the use of corticosteroids after ocular surgery, ocular adverse 
reactions that occurred in 5% to 15% of 
subject
s included corneal edema, ciliary and 
c
onjunctival hyperemia, eye pain, photophobia, posterior capsule opacification, anterior chamber 
cells, anterior chamber flare, conjunctival edema, and blepharitis. Other ocular adverse reactions 
occurring in 1% to 5% of 
subject
s included reduced visual acu
ity, punctate keratitis, eye 
inflammation, and iritis. Ocular adverse reactions occurring in less than 1% of 
subject
s included 
application site discomfort or irritation, corneal pi[INVESTIGATOR_612609], epi[INVESTIGATOR_227], eye pruritus, 
eyelid irritation and cru
sting, foreign body sensation, increased lacrimation, macular edema, 
sclera hyperemia, and uveitis. Most of these reactions may have been the consequence of the 
surgical procedure.
 
[IP_ADDRESS]
 
Potential Risks Associated with the APP13007 Formulation
 
 
 
 
 
 
 
 

Clinical Study Protocol:  CPN
-
301
 
Formosa Pharmaceuticals, Inc.
 
APP13007
 
 
Version 1.
3 
(Amendment 1)
 
CONFIDENTIAL
 
Page 
[ADDRESS_812173]
s enrolled into the study. The Risk Mitigation Plan is shown in 
Table 
2
.
 
1.5.3
 
C
ontraindications
 
 
APP13007
, as with other corticosteroids, is contraindicated in the presence of active viral 
diseases of the cornea and conjunctiva including epi[INVESTIGATOR_534215] (dendritic 
keratitis), vaccinia, and varicella, and also in 
subject
s with mycobacterial
 
infection of the eye and 
fungal diseases of ocular structures.
 
APP13007 must not be administered 
(i) 
to 
women of child
-
bearing potential
 
without
 
a negative 
urine pregnan
c
y test
 
on POD1 
prior to randomization 
and agreement to use 
highly 
effective 
contracep
tion 
or abstain from sexual activity 
from POD1 to POD22 
or 
(ii) 
to 
pregnan
t or
 
nursing 
(breast
-
feeding) 
woman
.
 
1.5.4
 
P
otential 
B
enefits
 
Topi[INVESTIGATOR_612610] a well
-
established therapy for the treatment of 
inflammation and pain 
after ocular surgery, with multiple marketed products currently available 
that utilize corticosteroids as the active ingredient such as dexamethasone (Maxidex
®
), 
prednisolone (PredForte®), loteprednol etabonate (Lotemax
®
, Inveltys
®
, Lotemax SM
®
),
 
and 
diflu
prednate (Durezol
®
). 
In all clinical trials, corticosteroid therapi[INVESTIGATOR_612611] a frequency 
of twice daily or more frequently. 
 
A
s
 
summarized in the APP13007 Investigator’s Brochure, 
in 
S
tudy CPN
-
201 
a greater 
proportion of 
subjects treated with APP130
07 
0.05% BID 
had complete clearing of anterior 
chamber cells 
and complete resolution of ocular pain 
compared to placebo
-
treated subjects. 
Th
us, 
it is likely that 
subjects
 
randomized to 
active 
APP13007 
will 
experience a 
clinically
-
meaningful 
reduction in in
flammation and pain following cataract surgery.
 
It is known from 
large 
clinical trials of products for the treatment of inflammation and pain after 
ocular surgery that a proportion of 
subject
s randomized to placebo improve in the days following 
surgery (Lo
temax
®
 
Product Insert 2018; Durezol
®
 
Product Insert 2017). Thus, there may be a 
marginal benefit 
observed in
 
some of the 
subject
s enrolled into the study 
who
 
are randomized to 
the matching vehicle 
placebo.
 

Clinical Study Protocol:  CPN
-
301
 
Formosa Pharmaceuticals, Inc.
 
APP13007
 
 
Version 1.
3 
(Amendment 1)
 
CONFIDENTIAL
 
Page 
[ADDRESS_812174]
s will be randomized 1:[ADDRESS_812175]
s randomized to 
active 
APP13007
 
may benefit from the 
treatment by [CONTACT_612638], while the risks associated with 
active 
APP13007 treatment are likely to be low and manageable. This assessment is supported by [CONTACT_612639] 
(
See 
Section 
1.3
)
 
and clinical studies (
See 
Section 
1.4
) that are 
summarized in 
detail in 
the APP13007
 
Investigator’s Brochure.
 
Subject
s randomized to placebo are not expected to benefit from the study treatment, but a 
proportion of 
subject
s receiving placebo may 
show improvement of inflammation
 
in the days 
following surgery. Furthermore, the risks to 
subject
s randomized to placebo in this study are 
mitigated as much as possible. Specifically, the protocol contains instructions for careful 
monitoring of safety and efficacy endpoints during the tr
ial to identify 
subject
s who show 
minimal improvement or worsening of the clinical conditions so that appropriate mitigation steps 
can be taken, including, but not limited to, withdrawal from study treatment and commencement 
of appropriate 
rescue medicatio
n
.
 
Overall, the risk:benefit analysis supports the evaluation of 0.05% APP13007 and matching 
vehicle placebo administered BID for 
[ADDRESS_812176] surgery.
 
 
Table 
2
:
 
Risk Mitigation Plan
 
Potential Risk
 
Management
 
Comments
 
Risk Associated with Lack of Efficacy
 
Minimal reduction or 
worsening of 
inflammation and pain 
endpoints or other 
factors suggesting lack 
of efficacy 
 
Inflammation and pain endpoints will be 
monitored during the study.
 
Guidance criteria and procedures for the 
rescue of 
subject
s are provided in 
Section 
9.4
 
of this protocol.
 
Minimal reduction or worsening of 
inflammation and pain endp
oints or 
other factors suggesting lack of 
efficacy 
 
Risk Associated with Unexpected Safety Events
 
Unexpected safety 
events 
 
Safety endpoints will be monitored during 
the trial. 
 
The Investigator will discuss unexpected 
safety events with the Study Medical 
Monitor who will then discuss 
unexpected safety events with the 
Sponsor to determine whether study drug 
should be stopped and rescue procedures 
commenced. 
 
The toxicology studies
 
with 
APP13007 indicate that there is a 
low risk of ocular toxicity. 
T
he 
risks of systemic exposure to CP 
following dermal
 
a
pplication
 
are 
well characterized
. 
 
 
 
 
 
 
 
Nevertheless
, the Investigator 
should be alert to the possibility 

Clinical Study Protocol:  CPN
-
301
 
Formosa Pharmaceuticals, Inc.
 
APP13007
 
 
Version 1.
3 
(Amendment 1)
 
CONFIDENTIAL
 
Page 
[ADDRESS_812177] of expected safety 
events is including in 
Section 
1.5.5
 
and in the APP13007 Investigator’s 
Brochure.
 
Risks Associated with the Corticosteroid Class
 
Intraocular pressure 
(IOP) increase
 
IOP
 
will be monitored during the study.
 
The protocol excludes 
subject
s who may 
be at increased risk of steroid
-
induced 
IOP increase, e.g. 
subject
s with a history 
of raised IOP
/glaucoma 
and 
subject
s with 
IOP >30 mmHg at the POD1
 
pre
-
randomization assessment. 
 
Section 
9.5
 
includes stoppi[INVESTIGATOR_612612]
-
lowering 
medication.
 
Afte
r Randomization, the management of 
IOP > 30 mmHg or IOP 
≥ 
21 mmHg 
AND an IOP increase 
>
 
10 mmHg from 
pre
-
dose baseline is described in 
Section 
9.5.2
.
 
The
re was no clinically
-
meaningful 
APP13007
-
related elevation of IOP 
in the
 
toxicology studies 
and 
in 
S
tudy CPN
-
201.
 
Prolonged use of CP may result in 
glaucoma with damage to the optic 
nerve, defects in visual acuity and 
fields of vision. 
 
An IOP 
≥ 30 mmHg af
ter 
randomization should be reported 
as an AE.
 
Cataracts
 
The lens structure and posterior capsular 
opacification (POC
) in the study eye will 
be monitored at each clinic visit 
throughout the study. The lens in the non
-
operated eye will be evaluated at 
Screening, 
Visit 6 (POD22) 
and Early 
Termination
/Withdrawal
 
visits.
 
 
 
 
 
 
 
 
 
 
 
 
 
Delayed Heal
ing
 
Subject
s with thinning of the cornea or 
sclera are excluded because of the greater 
risk of perforations with the use of topi[INVESTIGATOR_28709]. 
 
Protocol includes stoppi[INVESTIGATOR_612613], in 
consultation with the Study Medical 
Mo
nitor, is concerned about delayed 
healing.
 
Use of APP13007 may delay 
healing after cataract surgery and 
increase the incidence of bleb 
formation. 
There were no reports of 
delayed healing after cataract 
surgery in 
S
tudy CPN
-
201.
 
 

Clinical Study Protocol:  CPN
-
301
 
Formosa Pharmaceuticals, Inc.
 
APP13007
 
 
Version 1.
3 
(Amendment 1)
 
CONFIDENTIAL
 
Page 
[ADDRESS_812178] of ocular infections. Thi
s 
risk is likely to be low based on 
data from studies of other steroids 
products approved for the treatment 
of inflammation and pain after 
ocular surgery.
 
Hypothalamic
-
Pi[INVESTIGATOR_2117]
-
Adrenal Axis (HPA) 
Suppression
 
Monitor for symptoms and signs of 
reduced adre
nal function (including 
fatigue, muscle weakness, loss of appetite 
and weight, abdominal pain, nausea and 
diarrhea, low blood pressure, depression 
and irritability, salt craving and 
hypoglycemia).
 
The Investigator should discuss with the 
Study 
Medical Monitor who will then 
discuss with the Sponsor whether to stop 
study drug.
 
While s
ystemic absorption of 
topi[INVESTIGATOR_612614]
, this risk is likely to be 
very low 
 
 
 
-
 
 
 
-
 
Nevertheless
, 
I
nvestigators should 
be aware that the symptoms and 
signs of reduced adrenal function 
can be nonspecific and they should 
remain alert to the possibility that 
this may occur. 
 
Effects related to 
excessive corticosteroid 
pharmacology
 
Monitor for symptoms 
and signs of 
excess corticosteroid pharmacology such 
as Cushing's syndrome, hyperglycemia, 
and unmasking of latent diabetes mellitus.
 
The Investigator should discuss with the 
Study Medical Monitor who will then 
discuss with the Sponsor whether to stop 
stud
y drug.
 
These effects have been reported 
after dermal use of CP and result 
from systemic absorption of topi[INVESTIGATOR_612615].
 
T
he risk is likely to be 
very 
small
 
 
 
 
 
Pregnancy Category 
C/Fetal effects
 
Women of child
-
bearing potential 
are 
excluded from the study if they have a 
positive urine pregnancy test on POD1 
pre
-
randomization
 
and/or do not agree to 
use 
highly 
effective contraception or 
abstain from sexual activity
.
 
P
regnant and/or nursing
 
(breast
-
feeding) 
mothers 
are excluded from
 
the study.
 
Corticosteroids are known 
teratogens in laboratory animals 
when administered systemically at 
relatively low dosage levels.
 
 
 
 
 

Clinical Study Protocol:  CPN
-
301
 
Formosa Pharmaceuticals, Inc.
 
APP13007
 
 
Version 1.
3 
(Amendment 1)
 
CONFIDENTIAL
 
Page 
[ADDRESS_812179] been 
described with topi[INVESTIGATOR_612616] 
(See APP13007 
Investigator’s Brochure)
.
 
Other Potential Risks
 
 
 
 
 
 
 
 
 
-
 
 
 
 
 
 
 
 
 
Hypersensitivity 
Reactions 
 
Subject
s are excluded from the study if 
they have a history of hypersensitivity to 
CP, corticosteroids, 
 
 
 
 
If hypersensitivity reaction occ
urs, the 
Investigator should discuss with the Study 
Medical Monitor who will then discuss 
with the Sponsor Medical Monitor 
whether to stop study drug.
 
 
Adverse reactions 
reported in clinical 
studies evaluating the 
use of corticosteroids 
after ocular surge
ry.
 
Most of these adverse reactions may have 
been the consequence of the surgical 
procedure and should be managed 
according to standard
-
of
-
care procedures.
 
Ocular adverse reactions reported 
in 
completed clinical studies of 
APP13007 
are summarized in 
Section 
1.5.1
. 
 
 
 

Clinical Study Protocol:  CPN
-
301
 
Formosa Pharmaceuticals, Inc.
 
APP13007
 
 
Version 1.
3 
(Amendment 1)
 
CONFIDENTIAL
 
Page 
38
 
of 
89
 
 
S
TUDY 
O
BJECTIVES AND 
E
NDPOINTS
 
The objectives and corresponding study endpoints are
 
presente
d in
 
Table 
3
 
below:
 
Table 
3
:
 
Study Objectives and Endpoints
 
Objectives
 
Endpoints
 
Primary Efficacy Objective
 
The primary efficacy objective is to investigate 
the efficacy of APP13007 versus matching 
vehicle placebo for the treatment of 
inflammation and pain through post
-
operative 
day (POD) [ADDRESS_812180] surgery
 
in the study 
eye
.
 
Primary Efficacy 
Endpoints
 

 
The 
proportion of 
subjects
 
with 
Anterior 
Chamber Cell (ACC) 
Count = 0 
[ACC Grade = 
0] at post
-
operative day
 
8 
(POD8),
 
maintained 
through POD15 
 

 
The proportion of 
subjects
 
with Ocular Pain 
Grade = [ADDRESS_812181] surger
y 
in the study eye
.
 
Secondary Efficacy Endpoints
 

 
Proportion of subjects with ACC count = 0 
[ACC Grade = 0] at PODs 4, 8 and 15
 

 
Proportion of subjects with Ocular Pain Grade = 
0 at PODs 4, 8 and 15 
 

 
Proportion of subjects with Anterior chamber 
flare (ACF
) Grade = 0 at POD8 maintained 
through POD15 
 

 
Proportion of subjects with ACF Grade = 0 at 
PODs 4, 8 and 15
 

 
Mean 
change
-
from
-
baseline
 
in ACC Grade at 
PODs 4, 8, and 15
 

 
Mean 
change
-
from
-
baseline
 
in Ocular Pain 
Grade at PODs 4, 8 and 15
 

 
Mean 
change
-
from
-
base
line
 
in ACF Grade on 
PODs 4, 8 and 15 
 

 
Number of subjects rescued on or prior to each 
visit and overall
 

 
Mean 
change
-
from
-
baseline
 
in best corrected 
visual acuity by [CONTACT_21173][INVESTIGATOR_612598] 
(ETDRS) chart at PODs 4,
 
8 and 15
 
Clinical Study Protocol:  CPN
-
301
 
Formosa Pharmaceuticals, Inc.
 
APP13007
 
 
Version 1.
3 
(Amendment 1)
 
CONFIDENTIAL
 
Page 
[ADDRESS_812182] surgery.
 
Safety Endpoints
 

 
Adverse events (AEs) 
 

 
Best corrected visual acuity by [CONTACT_21173][INVESTIGATOR_612617] f
ro
m baseline to each 
post
-
surgery visit
 

 
Slit
-
lamp biomicroscopy
 
o
 
Change
-
from
-
baseline in ocular signs to 
each post
-
surgery visit
 

 
Dilated indirect ophthalmoscopy
 
o
 
Change
-
from
-
baseline in ocular signs to 
Visit 6 (POD22)
 

 
Intraocular pressure (IOP) at each visit and 
c
hange
-
from
-
baseline to Visit 6 (
PO
D22
)
 
measured with a Goldman
n applanation
 
tonometer
 
 
Clinical Study Protocol:  CPN
-
301
 
Formosa Pharmaceuticals, Inc.
 
APP13007
 
 
Version 1.
3 
(Amendment 1)
 
CONFIDENTIAL
 
Page 
40
 
of 
89
 
 
S
TUDY 
D
ESIGN
 
3.1
 
S
tudy 
D
esign 
O
verview
 
This Phase 3 study will evaluate 
0.05% 
APP13007 
in comparison to
 
the matching vehicle 
placebo in a randomized, parallel
-
group, double
-
masked fashion. 
Subject
s will have routine 
cataract surgery on Day 0 of the study and will be assessed the next day (POD1) after 
uncomplicated surgery for 
eligibility 
for
 
randomization to
 
study treatment.
 
Subject
s who experience postoperative inflammation on POD1 and who meet all other eligibility 
criteria will be randomized to one of two study treatments (either Treatment 1 or Treatment 2)
 
at 
a 1:1 ratio
:  
 

 
Treatment 1:  1 drop APP13007 t
wice daily (BID) (morning and evening) for 14 days 
instilled 
to the operated study eye
 

 
Treatment 2:  1 drop matching vehicle placebo BID (morning and evening) for [ADDRESS_812183]
s will 
be 
discharged from the study after
 
the assessments 
for
 
Visit 6 (
POD22
)
 
have been 
performed
.
 
3.2
 
Study Visit Overview
 
Th
is 
will include up to 
7
 
clinic visits (
including 
the surgery
 
day) over a range of 2
4
 
to 
approximately 
5
2
 
days
.
 
Note: 
T
he study drug will be dosed 
BID 
for 14 days.
 
3.2.1
 
Study 
Visits and Procedures
 
Visit 1
: Screening. Sign informed consent prior to the conduct of any study procedures or 
discontinuation of any medications related to this study. Screening will occur between [ADDRESS_812184] surgery. Review Inclus
ion and Exclusion criteria for eligibility. 
 
Between Screening and the day of surgery (Day 0), the prospective 
subject
s will be determined 
to be a suitable candidate for surgery during a pre
-
surgery medical assessment, where the routine 
medication list pre
scribed by [CONTACT_612640]
s (
S
ee 
Section 
5.4.2
).
 
Day 0/Day of Surgery
: 
Subject
s undergo routine cataract surgery via phacoemulsification and 
posterior chamber intraocular lens implantation according to the Investigator’s normal 
procedures. 
 
Clinical Study Protocol:  CPN
-
301
 
Formosa Pharmaceuticals, Inc.
 
APP13007
 
 
Version 1.
3 
(Amendment 1)
 
CONFIDENTIAL
 
Page 
41
 
of 
89
 
Visit 2
: POD1 will occur ~ [ADDRESS_812185] surgery. Review Inclusion and Exclusion 
cri
teria. Baseline pre
-
Randomization assessments (ocular inflammation, pain and safety 
assessments). Randomization of eligible 
subject
s. Instillation of first dose of study treatment in 
the operated study eye in the clinic under the supervision of Investigator or designee. 
 
Visit 3
: POD4 (± 1 day). Ocular inflammation, pain and safety assessments.
 
Visit 4
: POD8 (± 1 day). Ocular inflamma
tion, pain and safety assessments.
 
[Note: 
Subject
s will be contact[CONTACT_463815]14 to remind them to stop study drug 
after
 
that day 
and to bring the study drug bottle and dosing diary to the clinic the next day.]
 
Visit 5
: POD15 (+ 1 day). Ocular inflammation, p
ain and safety assessments.
 
Urine pregnancy 
test.
 
Visit 6
: POD22 (± 2 days). Ocular inflammation, pain and safety assessments. Final visit
.
 
 
A 
detailed 
summary of study events is provided in
 
Table 
1
 
(Schedule of Events) and a study 
design schematic is provided in
 
Figure 
1
 
(Study Schematic). 
 
3.2.[ADDRESS_812186]
-
operative inflammation and pain following ocular 
surgery.
 
 
The efficacy data from Part A of 
S
tu
dy CPN
-
201 
summarized in the APP13007 Investigator’s 
Brochure
 
show that APP13007 0.05% BID, compared to matching vehicle placebo, produce
d
 
a 
statistically and clinically
-
meaningful increase in the proportion of subjects who ha
d
 
an ACC 
Count = 0 at POD8 that 
was 
maintained through POD15.
 
 
Clinical Study Protocol:  CPN
-
301
 
Formosa Pharmaceuticals, Inc.
 
APP13007
 
 
Version 1.
3 
(Amendment 1)
 
CONFIDENTIAL
 
Page 
42
 
of 
89
 
A greater proportion of s
ubjects dosed 
with 
APP13007 
as compared to 
placebo 
had resolution of 
ocular pain
 
(
grade 
= 0) 
at POD4 
that was 
maintained through POD15
. 
 
The US FDA has agreed with the primary endpoints in this study at an End
-
of
-
Phase 2 meeting. 
 
3.3.3
 
R
ationale 
f
or 
D
osing 
R
egimen
 
The results from 
S
tudy CPN
-
201 
summarized in the APP13007 Investigator’s Bro
chure 
show 
that 0.05% APP13007 BID 
as compared to its matching vehicle placebo 
produced a clinically
-
meaningful 
reduc
tion of
 
inflammation and pain after cataract surgery. 
In addition, all APP13007 
dosing 
regimens were well
-
tolerated with a safety profile s
imilar to the matching vehicle 
placebos. 
 
These data support the selection of 1 drop of 0.05% APP13007 administered BID for 14 days as 
the dosage regimen for th
is
 
Phase 3 clinical stud
y
.
 
The US FDA has agreed with the selection of the dosing regimen to be 
used in this study at an 
End
-
of
-
Phase 2 meeting. 
 
Clinical Study Protocol:  CPN
-
301
 
Formosa Pharmaceuticals, Inc.
 
APP13007
 
 
Version 1.
3 
(Amendment 1)
 
CONFIDENTIAL
 
Page 
[ADDRESS_812187] surgery and 
(i
) 
meet the inclusion criteria, including 
hav
ing
 
>10 anterior chamber cells in the study eye 
(operated eye) at POD1
,
 
and 
(ii) 
do 
not
 
meet any of the exclusion criteria
,
 
will be 
randomized to 
study treatment
.
 
4.[ADDRESS_812188] meet the following criteria:
 
At the Screening Visit (Visit 1):
 
1.
 
Provide signed and dated informed consent
 
2.
 
Age 
≥ [ADDRESS_812189] been permanently sterilized or are postmenopausal. 
Postmenopausal is defined as amenorrhea for a minimum of 12 months (without an 
alternative medical cause). 
Note: 
Pregnant women or 
nursing 
(breast
-
feeding) 
mothers
 
are 
excluded fro
m the study
. 
 
4.
 
W
omen
-
of
-
childbearing
-
potential to be eligible for enrollment if they have a negative urine 
pregnancy test on POD1 prior to Randomization
 
and they agree to abstain from sexual 
activity or use a highly effective contraceptive such as occlusive
 
cap (diaphragm or 
cervical/vault cap) plus spermicidal agent (foam/gel/film/cream/suppository), oral 
contraceptive, injectable progesterone, implant of etonogestrel or levonorgestrel, estrogenic 
vaginal ring, percutaneous contraceptive patches, or intraut
erine device 
from POD1 to Visit 6 
(POD22)
.
 
5.
 
Expected to undergo unilateral
 
uncomplicated cataract extraction via phacoemulsification 
and posterior chamber intraocular lens implantation in one eye (designated the ‘Study Eye’).
 
6.
 
Have a pin
-
hole corrected visua
l acuity without other correction of 
≤ 1.3 logarithm of the 
minimum angle of resolution (logMAR) in the study eye to be operated and contralateral eye 
as measured using an Early Treatment Diabetic Retinopathy Study (ETDRS) chart at Visit 1. 
Subject
s who are unable to read the lines in an ETDRS chart because of the density of the 
cataract in the study eye may be enrolled if, in the opi[INVESTIGATOR_689], there is no 
other significant ocular pathology that would account for the low visual acuity
.
 
Clinical Study Protocol:  CPN
-
301
 
Formosa Pharmaceuticals, Inc.
 
APP13007
 
 
Version 1.
3 
(Amendment 1)
 
CONFIDENTIAL
 
Page 
44
 
of 
89
 
7.
 
Willing and able to comply with study requirements and visit schedule; Able to either self
-
administer study medication or have someone available (e.g., spouse, caregiver, etc.) who 
can administer study medication according to the study schedule and instr
uctions 
 
4.2.1
 
Additional Inclusion Criteria on Postoperative Day (POD) 1/Day of 
Randomization (Visit 2)
 
8.
 
Have undergone unilateral cataract extraction via phacoemulsification and posterior chamber 
intraocular lens implantation in the study eye without any additi
onal procedures or
 
c
omplications that would, in the opi[INVESTIGATOR_689], interfere with study procedures 
or confound study objectives
 
9.
 
No significant ocular pathology affecting visual acuity that is identified after posterior 
chamber intraocular len
s implantation in the study eye
.
 
10.
 
Have 
≥ 10 cells in the anterior chamber (excluding red blood and pi[INVESTIGATOR_482429])
 
11.
 
Have an IOP 
≤ 30 mmHg. 
Note: If the IOP is elevated post
-
surgery, the investigator may use
 
non
-
prostaglandin based
 
IOP
-
lowering medication(s) a
t their 
discretion 
on the day of surgery
 
(Day 0) only
. The
 
IOP 
will
 
be measured 
and recorded 
on POD1 
to determine eligibility for 
Randomization.
 
 
4.3
 
Exclusion Criteria
 
Participants will be excluded if they meet any of the following criteria: 
 
1.
 
Have a known sen
sitivity or allergy to clobetasol propi[INVESTIGATOR_16847], corticosteroids, or any of the 
study medication’s components including benzalkonium chloride and soybean lecithin or any 
routine medication required during cataract surgery or for the conduct of study procedure
s.
 
2.
 
Have an ACC 
count 
> 0 or any evidence of intraocular inflammation (e.g., flare) in either eye 
at the Screening visit.
 
3.
 
Have a Grade > [ADDRESS_812190] active or chronic/recurrent ocular or systemic disease that is uncontrolled and could 
affect wound healing and/or 
resolution of inflammation after cataract surgery.
 
6.
 
Suspected or known malignancy or be currently receiving antineoplastic therapy. 
Note:
 
subject
s with basal cell carcinoma will not be excluded unless the Investigator believes 
that the condition has the pot
ential to interfere with study procedures or analysis of results.
 
Clinical Study Protocol:  CPN
-
301
 
Formosa Pharmaceuticals, Inc.
 
APP13007
 
 
Version 1.
3 
(Amendment 1)
 
CONFIDENTIAL
 
Page 
45
 
of 
89
 
7.
 
Are using certain medications, namely:
 
i.
 
Subject
s receiving treatment for macular degeneration 
(
in 
either eye) 
with Eylea
®
 
(aflibercept), Avastin
®
 
(bevacizumab), Lucentis
®
 
(ranibizumab) 
Beovu
®
 
(brolucizumab
-
dbll)
 
or Visudyne
®
 
(verteporfin) are excluded
.
 
ii.
 
PROKERA (preserved amniotic membrane) is 
excluded
 
from 1 year prior to the Screening visit 
to the end of the study
.
 
iii.
 
Anti
-
inflammatory agents, analgesics (including opi[INVESTIGATOR_2438], narcotics, nonsteroid
al anti
-
inflammatory drugs (NSAIDs), aspi[INVESTIGATOR_248], acetaminophen and other pain medications) or 
immune
-
modulating agents systemically or in either eye from the beginning of the 
‘Washout’ period in the 
List 
of Prohibited Medications
 
(
Section 
5.4.2
) 
until after the 
POD15 
assessments
,
 
but preferably until after the POD22 assessments. 
Note: 
(i)
 
acetaminophen is permitted on the day of surgery; (ii) 
immunizations/vaccinations are 
permitted before and during the study.
 
iv.
 
Use of any of the prohibited medications listed 
Section 
5.4.2
 
within a time period prior to 
surg
ery that is less than the minimum ‘washout’ period noted in
 
Table 
4
. 
[NOTE:
 
(i)
 
These medications may not be used from the beginning of the ‘Washout’ 
period in 
Table 
4
 
until after the POD15 assessments
, 
but preferably until after the POD22 
assessments
; NOTE: (ii) Medications for 
anesthesia
 
related to cataract surgery
, ocular 
pain contr
ol and 
non
-
prostaglandin
-
based therapy for the treatment of raised intraocular 
pressure (IOP)
 
are allowed on the day of surgery only]
 
v.
 
Non
-
approved drugs or investigational products other than the study drug in
 
this study 
are prohibited from [ADDRESS_812191] an IOP < 5 mmHg or > 22 mmHg in 
either eye or a difference of > [ADDRESS_812192] active or a history of chronic or recurrent inflammatory eye disease (e.g., iritis, 
scleritis, uveitis, 
iridocyclitis, rubeosis iridis) in the study eye.
 
13.
 
Have evidence of acute external ocular infections (bacterial, viral and/or fungal infections 
including vaccinia, varicella and other viral diseases of the cornea and conjunctiva); 
tuberculosis of the eye; i
ntraocular infections, active chalazion, or uncontrolled severe 
blepharitis in the study eye.
 
14.
 
Have corneal dystrophies
, including corneal guttae and Fuchs’ dystrophy
,
 
or dysthyroid 
ophthalmopathy in the study eye.
 
Clinical Study Protocol:  CPN
-
301
 
Formosa Pharmaceuticals, Inc.
 
APP13007
 
 
Version 1.
3 
(Amendment 1)
 
CONFIDENTIAL
 
Page 
[ADDRESS_812193] uncontrolled and clinically significa
nt dry eye syndrome in the study eye (mild dry eye 
with the use of artificial tears is allowed).
 
16.
 
Have proliferative diabetic retinopathy, significantly compromised macular function; 
significant macular disease; have clinically
-
significant macular edema or 
a history of cystoid 
macular edema in the study eye; have cup:disc ratio > 0.8.
 
17.
 
Have had corneal or retinal surgery (laser or incisional) in the study eye within [ADDRESS_812194]
udy period in 
the study eye (other than cataract surgery).
 
18.
 
Have ocular surgery planned, scheduled or performed on the contralateral eye within the 
[ADDRESS_812195]
-
surgical outcome (including, but not limited to intraocular inflammation, IOP or 
the normal healing process).
 
20.
 
Requ
ire the use of a contact [CONTACT_350500] a collagen shield within [ADDRESS_812196] surgery 
or for the remainder of the study period in either eye.
 
21.
 
Require use of non
-
diagnostic topi[INVESTIGATOR_612618]: mydriatics, anesthetics, 
antiseptics, balanced salt solution, viscoelastics, osmotic agents (e.g., Muro 128), 
prophylactic antibiotics, non
-
prostaglandin analog IOP
-
lowering agents for IOP increases 
on 
t
he day of
 
cataract surgery, lid scrubs for mild blepharitis, or artificial tears for the 
management of mild dry eye.
 
22.
 
In the opi[INVESTIGATOR_871], have the potential for ocular hemorrhage in the study eye 
that may interfere with evaluation of post
-
su
rgery inflammation.
 
23.
 
Have a planned use of or use of femtosecond laser or any other ophthalmic surgical 
procedure (e.g., vitrectomy, relaxing incisions, iridectomy, conjunctival excisions, use of iris 
hooks or other iris dilators, etc.) in addition to the cataract extraction p
rocedure via 
phacoemulsification and PCIOL implantation in the study eye.
 
24.
 
Have a planned use of or use anterior capsule staining for capsulorhexis (i.e., trypan blue) 
during cataract surgery.
 
25.
 
Have 
planned
 
to participate in another clinical trial during the
 
duration of this study.
 
26.
 
Have participated in another clinical study or received any investigational product within the 
past [ADDRESS_812197] su
rgery is for the eye that was the ‘non
-
study’ 
eye in that study. 
 
27.
 
Have any other condition that the Investigator determines should exclude the 
subject
 
from 
the trial.
 
28.
 
Are an employee of the clinical site that is directly involved in the management, 
adminis
tration, or support of this study or are an immediate family member of the same.
 
 
Clinical Study Protocol:  CPN
-
301
 
Formosa Pharmaceuticals, Inc.
 
APP13007
 
 
Version 1.
3 
(Amendment 1)
 
CONFIDENTIAL
 
Page 
[ADDRESS_812198]
 
will be supplied with a single dropper bottle throughout the study period 
(see
 
Section 
5.1.2
 
below). Individual dropper bottles will be labelled according to FDA 
requirements. The labels will include the following information:
 

 
Protocol number: CPN
-
30
1
 

 
Bottle number
 

 
Subject
 
Number
 

 
Study Eye: R or L
 

 
Content: APP13007 
 
or 
P
lacebo
 
 
 

 
For Topi[INVESTIGATOR_612619]. Keep Out of the Reach of Children.
 

 
CA
UTION: New drug 
–
 
Limited by [CONTACT_4496] (or [LOCATION_002]) Law to Investigational Use
 
 
Acquisition
 
I
ndividual dropper bottles packaged with proper labels will be shipped to each study site from a 
central drug product
 
labeling,
 
packaging and distribution vendor. Sufficient quantity of 
APP13007 and matching vehicle placebo will be provided to each site to accommodate the 
initial 
randomization
 
rate
, with the option to resupply high
-
enrolling sites
. Once a 
subject
 
is 

Clinical Study Protocol:  CPN
-
301
 
Formosa Pharmaceuticals, Inc.
 
APP13007
 
 
Version 1.
3 
(Amendment 1)
 
CONFIDENTIAL
 
Page 
[ADDRESS_812199]
 
number based on the randomization schedule.
 
Storage and Stability
 
 
5.1.2
 
Study Drug Dosing and Administration
 
[IP_ADDRESS]
 
Dispensing and Replacing Study Drug
 
Study drug will be dispensed by [CONTACT_612641]. One bottle will be dispensed 
to each 
subject
 
for the duration of the study 
treatment period. If the 
subject
 
discontinues study drug, the study drug bottle should be collected 
at the next 
clinic 
visit.
 
If a 
subject
 
loses the single bottle of study drug or if it becomes compromised (e.g
., 
damaged or 
dropped into the toilet) prior to the POD15 visit, the bottle of study drug should be replaced as 
soon as possible. The site should use the IWRS system to identify a replacement bottle. 
Subject
s 
are instructed to notify the study site as soon
 
as the study drug bottle is lost or compromised, so 
that the site can arrange for the replacement bottle to be provided as soon as possible. Any 
missed doses due to loss of study drug bottle will be documented in the diary and eCRF.
 
 
F
ailure to dose 
from
 
the replacement bottle
 
(issued prior to POD 15)
 
will be considered a 
protocol deviation
.
 
[IP_ADDRESS]
 
Subject
 
Diaries
 
A study diary will be given to each 
subject
 
at the visits indicated on the Schedule of Events 
(
Table 
1
). The 
subject
 
will record the date and time of each dose of study drug as well as the 
total number of drops applied (including missed drops) and the number of drop(s) instilled 
correctly into the conjunctival sac of 
the 
study eye
 
at each dosing time
. 
The 
diary will remind the 
subject
 
to
 
instill
 
the study drug 
a minimum of [ADDRESS_812200]
 
for compliance
-
related issues.
 

Clinical Study Protocol:  CPN
-
301
 
Formosa Pharmaceuticals, Inc.
 
APP13007
 
 
Version 1.
3 
(Amendment 1)
 
CONFIDENTIAL
 
Page 
49
 
of 
89
 
[IP_ADDRESS]
 
Study Drug Compliance
 
Site personnel will record the dosing record taken from the diary into the eCRF.
 
This will 
include the number of drop(s) applied in the study eye, date/time of application and verification 
that no other drugs were administered within [ADDRESS_812201]
ered in the study eye within 5 minutes of 
instillation of study drug, this will be 
recorded in the eCRF as a protocol deviation. 
Instillation of 
the study drug in the non
-
study eye will be recorded as a protocol deviation.
 
[IP_ADDRESS]
 
Study Treatments
 
The treatments a
re as follows: 
 

 
Treatment 1:  1 drop APP13007 twice daily (BID) (morning and evening) for 
14
 
days 
instilled 
to the operated 
study 
eye
 

 
Treatment 2:  1 drop matching vehicle placebo BID (morning and evening) for 
14
 
days 
instilled 
to the operated 
study 
eye
 
 
[IP_ADDRESS]
 
S
tudy Drug Dosing
 
Study drug (APP13007 
or 
matching vehicle placebo) will be supplied in an eye drop bottle with 
a drop tip, and the bottle is labeled in accordance with FDA regulations for 
investigational 
drug. 
One bottle will be dispensed to each 
subject
 
t
hroughout the study. Study drug will be self
-
administered twice daily as indicated per protocol by [CONTACT_612642] (study) eye. 
 
If the 
subject
 
misses the conjunctival cul
-
de
-
sac when dosing the first drop of study drug, the 
subject
 
should use a tissue to wipe away the study drug around the eye, and then instill a second 
drop into the conjunctival cul
-
de
-
sac so that at least one drop of study dru
g is administered into 
the study eye. If the second drop also misses the conjunctival sac, then the 
subject
 
should record 
the missed dose in the diary, but should not instill a 
third
 
drop.
 
Study drug should be administered twice daily. If other concomitant
 
eye drops/drugs are to be 
instilled into the study eye, the study drug should be instilled first followed by a minimum of a 
[ADDRESS_812202] dose should be 
instilled
 
in the morning and the second dose 
instilled
 
a minimum of 6 hours, but preferably 8 to 12 hours, later. The number of drops 
instilled
 
and the date/time of instillation of each dose must be recorded by [CONTACT_612643]
’s 
Clinical Study Protocol:  CPN
-
301
 
Formosa Pharmaceuticals, Inc.
 
APP13007
 
 
Version 1.
3 
(Amendment 1)
 
CONFIDENTIAL
 
Page 
[ADDRESS_812203] accountability of 
APP13007
 
and matching vehicle placebo. Accountability will be ascertained by [CONTACT_612644], along with bottle ID numbers, 
sent to the site and 
the number of bottles 
dispensed (used), 
unused or un
-
dispensed (along with bottle ID numbers) 
at the time of reconciliation. In addition, the number of bottles of study drug (along with bottle 
ID numbers) dispensed and returned will al
so be accounted for.
 
Clinical trial materials
 
will be shipped to the investigational sites under sealed conditions
 
with a 
temperature tracking device
. Study drugs shipment records will be verified by [CONTACT_612645] (number of bottles and bottle ID 
numbers) received at the site. Accurate records of receipt and disposition of the study drug (e.g., 
dates, number of bottle
s 
and each bottle ID number 
received, 
dispensed, lost or compromised, 
and return
ed) 
and subject number associated with the bottle ID number 
must be maintained by 
[CONTACT_21438]/her designee. 
 
 
 
At the end of th
e study, all study materials, including any used (and returned) and unused study 
drugs bottles, even if empty, will be returned to the drug packaging and distribution vendor in 
accordance with Sponsor or designee’s standard operations procedures (SOPs), fo
llowing 
approval by [CONTACT_1034]. All returns of study drugs will be documented. The study monitor or 
designee will verify drug accountability. All drug accounting procedures must be completed 
before the study is considered complete.
 
5.[ADDRESS_812204]
s, the Investigators and the study site staff responsibl
e for managing and 
administering the study
, communicating with the study subjects,
 
and/or performing assessments 
of study endpoints will be masked to study treatment assignment of each 
subject
 
throughout the 
entire study. 
 
The Study Medical Monitor will re
main masked throughout the study unless unmasked 
information becomes necessary as part of the management of a medical emergency or SAE for a 
particular 
subject
, as described below.
 

Clinical Study Protocol:  CPN
-
301
 
Formosa Pharmaceuticals, Inc.
 
APP13007
 
 
Version 1.
3 
(Amendment 1)
 
CONFIDENTIAL
 
Page 
[ADDRESS_812205], data collection or management
. The EDC/IWRS 
system will be used for randomization and unmasking of tr
eatment assignment when necessary. 
 
In case of a medical emergency or occurrence of an SAE, the Investigator will treat each 
subject
 
as needed and should contact [CONTACT_10542], if required, to discuss whether it is 
appropriate to unmask the 
sub
ject
 
to reveal the 
subject
’s treatment assignment. If deemed 
necessary, the Investigator will log into the EDC system to obtain unmasking information. The 
Investigator must use their individual login information to gain access to the unmasking 
information.
 
The Investigator will also notify the IRB and the CRO managing and monitoring 
this study when treatment assignment for a particular 
subject
 
is unmasked. The Study Medical 
Monitor will notify the Sponsor Medical Monitor when treatment assignment for a part
icular 
subject
 
is unmasked due to 
a medical emergency or 
SAE. It is important to note that the study 
treatment assignment will be revealed only on a 
subject
-
by
-
subject
 
basis and the treatment 
assignment of the other 
subject
s in the study, as described abov
e, will remain masked until the 
final database is locked. Once the treatment assignment for a specific 
subject
 
is unmasked, it will 
be made available to the Investigator and the Sponsor. Other personnel involved in the 
monitoring or conduct of this study w
ill remain masked.
 
5.4
 
P
rior
/Concomitant Therapy and Rescue Medication
 
All 
prior/
concomitant medications (prescription and OTC) a 
subject
 
is receiving at the Screening 
visit and 90 days prior to the Screening visit and taken throughout the course of the study will be 
recorded 
as 
follows
:
 
  
 

 
Information regarding the duration of 
a 
prior/
concomitant 
medication
 
(including start and 
stop dates)
, dose, frequency, site of dosing (right eye, left eye, both eyes, non
-
ocular) and the 
reason why the 
prior/
concomitant medication is being taken will
 
be recorded
 
in 
the source 
documents 
and 
in the 
Prior/
Concomitant Medications (ConMeds) page of the eCRF
. 
 

 
M
edications used for the surgical procedure 
will be recorded in the source documents and in 
the ConMeds page of the eCRF. 
 

 
The ocular medications (mydriatics and topi[INVESTIGATOR_39671]) used to perform the dilated 
ophthalmoscopy and Goldman
n applanation
 
tonom
etry 
assessments 
will be recorded in 
the 
source documents only.
 
 
Note: The information on 
prior/
concomitant medications will be used to determine whether a 
subject
 
is taking or has taken prohibited medications as outlined in 
Section 
5.4.2
.
 
Clinical Study Protocol:  CPN
-
301
 
Formosa Pharmaceuticals, Inc.
 
APP13007
 
 
Version 1.
3 
(Amendment 1)
 
CONFIDENTIAL
 
Page 
[ADDRESS_812206] 
evidence of persistent or worsening inflammation 
as described in 
Section 
9.4
 
may be rescued and placed on appropriate alternate therapy. The choice of rescue medication 
is at the Investigator's discretion. Rescue medication should be entered into the eCRF with 
annotation indicating that the medication was used for r
escue.
 
Rescued 
subject
s will be considered as treatment failures, 
and 
the need for rescue therapy will 
not be considered an adverse event (AE). Rescued 
subject
s 
will stop study drug and 
should not 
be withdrawn from the study, 
and 
will be
 
assessed 
at 
each subsequent visit
, if possible, through 
completion of the Visit 6 
(POD22) 
assess
ments 
or until the Investigator has deemed the 
subject
 
is stable and can be released from the study as detailed in 
Section 
6.[ADDRESS_812207] provide signed informed consent before any prior medication is changed or 
discontinued because of participation in this study. The following medications may not be used 
after randomization 
as indicated below
. If used prior to surgery (Day 0), the medications must 
have been used in a timeframe that equals or exceeds the minimum ‘washout’ period noted
 
below
. 
 
The following medications are prohibited:
 
i.
 
Eylea
®
 
(aflibercept), Avastin
®
 
(bevacizumab), Lucentis
®
 
(ranibizumab)
, 
Beovu
®
 
(brolucizumab
-
dbll)
 
or Visudyne
®
 
(verteporfin)
 
(in either eye)
.
 
ii.
 
PROKERA (preserved amniotic membrane) is excluded
 
from 1 year prior to the Screening visit 
to the end of the study
.
 
iii.
 
Anti
-
inflammatory agents, analgesics (including opi[INVESTIGATOR_2438], narcotics, nonsteroidal anti
-
inflammatory drugs (NSAIDs), aspi[INVESTIGATOR_248], acetaminophen and other pain medications) or 
immune
-
modulating agents systemically or in either eye from the beginning of the 
‘Washo
ut’ period in 
Table 
4
 
until after the POD15 
assessments
, 
but
 
preferably until after 
the POD22 assessments
. 
Note:
 
(i)
 
acetaminophen is permitted on the day of surgery; 
(
ii)
 
immunizations/vaccinations are permitted before and during the study.
 
iv.
 
Use of any of the prohibited medications listed 
Table 
4
 
below within a time period prior 
to surgery that is less than the minimum ‘washout’ period noted in the table. 
NOTE:
 
(i)
 
These medications may not be used from the beginning of the ‘Washout’ 
p
eriod in 
Table 
4
 
until after the POD15 
assessments
, 
but
 
preferably until after the 
POD22 assessments
; 
NOTE: (ii) Medications for anesthes
ia
 
related to cataract surgery
, 
ocular pain control and non
-
prostaglandin
-
based management of raised intraocular 
pressure (IOP) are 
allowed o
n the day of surgery only
.
 
Clinical Study Protocol:  CPN
-
301
 
Formosa Pharmaceuticals, Inc.
 
APP13007
 
 
Version 1.
3 
(Amendment 1)
 
CONFIDENTIAL
 
Page 
[ADDRESS_812208]
 
has been released from the 
study.
 
Table 
4
:
 
P
rohibited 
M
edications and 
M
inimum 
W
ashout 
P
eriods
 
Medication
 
Minimum ‘Washout’ 
Period Prior to Day [ADDRESS_812209] cell stabilizers
 
2 days
 
Ocular antihistamines
 
2 days
 
Ocular and nasal decongestants
 
2 days
 
All eye drops (except antibiotic eye drops considered to be part of pre
-
cataract surgery 
standard
-
of
-
care). Note: Antibiotics with anti
-
inflammatory activity and Besifloxacin Ophthalmic suspension are not 
permitted. Note: (i) Artificial tears are allowed, but should not be used 
within 10 minutes of study procedures or medication dosing; (ii) s
pecific 
restrictions for ocular products are listed below.
 
2 days
 
Topi[INVESTIGATOR_243874] 
 
14 days
 
Topi[INVESTIGATOR_409464]
 
7 days
 
Topi[INVESTIGATOR_612620]
 
7 days
 
Systemic anti
-
inflammatory agents including acetaminophen, NSAIDS, 
acetylsalicylic acid (aspi[INVESTIGATOR_248]), and Lifitegrast. 
 
Note: (i) Use of acetylsalicylic acid for cardiovascular prophylaxis 
(i.e.,
 
81
 
mg dose QD) is allowed if dosage has been stable for at leas
t 
30
 
days prior to surgery and will remain stable for the duration of the 
study (ii) Acetaminophen may be administered as needed pre
-
 
and post
-
operatively on the day of surgery
, 
(iii) 
Over
-
the
-
Counter preparations 
such as Fish Oils, Turmeric and 
Ginseng that may have mild anti
-
inflammatory effects are allowed
.
 
7 days
 
Topi[INVESTIGATOR_612602] (use of 
topi[INVESTIGATOR_2855] 0.1% hydrocortisone dermal preparations for less than 3 days over 
a small area of skin [~2 inches x ~2
 
inches] are allowed).
 
14 days
 
Systemic (oral, injectable), inhaled and/or nasal corticosteroids
 
21 days
 
Systemic analgesics/pain relievers such as gabapentin, pregabalin, opi[INVESTIGATOR_612595]: Marijuana/CBD
-
containing products have the same washout 
restrictions a
s
 
“Systemic Analgesics” 
because they can affect pain 
perception
 
14 days
 
Medications for benign prostatic hypertrophy (BPH) (e.g., finasteride
, 
α
-
1
 
adrenergic receptor antagonists
)
 
are allowed based on the judgment of 
the 
investigator
. 
Note:
 
Investigators should consider 
the potential risk of 
intraoperative floppy iris syndrome in
 
subjects who are taking or have 
taken 
α
-
1 adrenergic receptor antagonists (eg. 
tamsulosin, silodosin, 
alfuzosin
)
.
 
Stable dose for 
28 days
 
Topi[INVESTIGATOR_612603]
 
60 days
 
Periocular injection of corticosteroid
 
28 days
 
Clinical Study Protocol:  CPN
-
301
 
Formosa Pharmaceuticals, Inc.
 
APP13007
 
 
Version 1.
3 
(Amendment 1)
 
CONFIDENTIAL
 
Page 
54
 
of 
89
 
Medication
 
Minimum ‘Washout’ 
Period Prior to Day 0
 
Intraocular treatment with corticosteroid 
-
 
dexamethasone drug delivery 
system
 
90 days after 
implantation
 
Intraocular treatment with 
corticosteroid 
–
 
fluocinolone acetonide drug 
delivery system
 
48 months after 
implantation
 
Stable doses of anticholinergics and antidepressants are allowed. 
Alterations of the dose of anticholinergics and antidepressants (other than 
for prn use as a sleep 
aid) may be allowed following consultation with the 
Study Medical Monitor. Anticholinergic eye drops used to dilate the eye 
are allowed. Systemic anticholinergic drugs are allowed on the day of 
surgery. 
 
 
Note 1
 
For anti
-
depressants used to treat 
depression: (i) Medication must not be 
washed
-
out for the purpose of enrollment in the study; (ii) Stable doses of 
anti
-
depressants are allowed; (iii) When the dose of an anti
-
depressant has 
been altered, the subject needs to be on the stable altered dose 
for at least 
90 days prior to the day of surgery (Day 0).
 
 
Note 2
 
For anti
-
depressants used to treat pain: (i) The instructions provided for 
systemic analgesics/pain relievers apply, viz. at least a 14 day washout of 
the medication is required prior to the
 
day of surgery (Day 0) continuing 
until the POD15 assessments have been completed.
 
See Note 1 and Note 2
 
 
Clinical Study Protocol:  CPN
-
301
 
Formosa Pharmaceuticals, Inc.
 
APP13007
 
 
Version 1.
3 
(Amendment 1)
 
CONFIDENTIAL
 
Page 
[ADDRESS_812210]
 
Refer to the Schedule of Events (
Table 
1
) for the list of study procedures/assessments to be 
conducted at each visit.
 
Data should be entered into the eCRF as soon as possible, preferably within [ADDRESS_812211] Number 
–
 
assigned
 
upon Screening examination.
 
Randomization Number 
–
 
assigned by [CONTACT_612646] a 
subject
 
on POD1.
 
Bottle Number 
–
 
associated with the Randomization Number, assigned by [CONTACT_10966].
 
If a 
subject
 
requires
 
a replacement study drug bottle, then a replacement Bottle Number will be 
identified through IWRS.
 
6.2
 
Description of Study Visits
 
6.2.1
 
Visit 1 
-
 
Screening
 
The Screening visit should occur no more than 28 days and no less than one (1) day prior to 
surgery. After o
btaining written informed consent and HIPAA authorization, site staff will 
perform the assessments as shown in the Schedule of Events (
Table 
1
). All ocular
 
assessments 
must be performed o
n both eyes at the Screening visit.
 
If surgery is not performed on the p
lanned
 
scheduled day such that screening procedures would 
fall outside of the [ADDRESS_812212]
 
would qualify for 
the study if a procedure/assessment 
is 
repeated/redone
 
(
in this case, the 
subject k
eeps the 
same 
subject number)
. 
Note: If subject who 
has failed
 
screen
ing
 
is rescreened at a later time, the 
subject will be assigned a new subject number. 
 
Subject
s who sign the informed consent form (ICF) and have 
undergone 
study 
procedures/assessments, b
ut do not meet eligibility criteria any time prior to randomization on 
POD1 will be considered as screen failures. 
Limited information
 
on screen failures will be 
transcribed to the eCRF.
 
After 
the 
screening 
assessments
 
and before surgery, the 
subject
 
may h
ave 
a pre
-
surgery medical 
assessment to determine 
whether
 
the 
subject
 
is a suitable candidate for surgery
. At this time
, the 
Clinical Study Protocol:  CPN
-
301
 
Formosa Pharmaceuticals, Inc.
 
APP13007
 
 
Version 1.
3 
(Amendment 1)
 
CONFIDENTIAL
 
Page 
[ADDRESS_812213] surgeon should be reviewed to rule out 
prohibited medications (
Table 
4
, 
Section 
5.4.2
). 
 
6.2.2
 
Day of Surgery (Day 0)
 
Prior to surgery, the surgeon’s routine medication list shou
ld be reviewed 
to exclude
 
prohibited 
medications
 
(
Table 
4
,
 
Section 
5.4.2
)
. Surgery should preferably be scheduled in the morning to 
accommodate BID dosing on POD1. 
However, if surgery has to be scheduled in the afternoon, 
subjects should still instill two doses of 
study drug on POD1 at least 6 hours apart.
 
On Day 0, the surgeon will perform his/her routine cataract surgical procedure using 
phacoemulsification and implantation of a posterior chamber intraocular lens in the operated eye 
following the surgeon’s usual p
re
-
operative, operative, and post
-
operative procedures (with the 
exception of avoiding use of prohibited medications). 
Aqueous release procedures are not 
permitted.
 
Following surgery, the following should be performed:
 

 
Give the 
subject
 
instructions regardi
ng routine post
-
surgical care and instructions regarding 
the use of concomitant medications and restricted medications during the study.
 

 
Record surgery parameters (surgery time, phaecoemulsion energy and an assessment of 
surgery difficulty) in the source d
ocuments and eCRF.
 

 
Record the m
edications routinely administered 
for 
cataract surgery in the source documents
.
 
These medications will be 
reported as being used for 
routine cataract surgery
.
 

 
If a medication is administered due to an AE, the medication must 
be entered 
in the source 
documents, indicating that the medication was used to treat an AE
. 
 

 
If a non
-
prostaglandin medication is used to lower IOP, the medication must be entered in the 
source documents and in the ConMeds page of the eCRF.
 

 
AEs and ConMeds
 
associated with an AE 
should only be recorded 
in the source
 
document
 
on 
Day [ADDRESS_812214]
 
returns 
for Visit 2 on 
POD1.
 

 
Only for subjects who are randomized, enter the medications routinely used for cataract 
surgery and concomitant medications in the ConMeds page of the eCRF and AEs in the AE 
page of the eCRF.
 

 
Schedule the 
sub
ject
 
to return to the clinic on the following day
, ie., 
POD1
,
 
in the morning 
(
if
 
possible).
 
6.2.3
 
Visit 2 
-
 
POD1 
(
Day of Randomization
)
 
Subject
s will return to the clinic for the study visit on POD1
 
between 18 to 34 hours following 
conclusion of surgery on Day 0. This visit should be scheduled in the morning, as much as 
Clinical Study Protocol:  CPN
-
301
 
Formosa Pharmaceuticals, Inc.
 
APP13007
 
 
Version 1.
3 
(Amendment 1)
 
CONFIDENTIAL
 
Page 
[ADDRESS_812215] 6 hours apart.
 
All assessments will be performed as shown in the Schedule of Events (
Table 
1
). 
Ocular 
assessments will be performed only 
o
n the operated, study eye
.
 
The site will review eligibility criteria (
Section 
4.2
 
and 
Section 
4.3
) to determine if the 
subject
 
qualifies for randomization. If the 
subject
 
meets all criteria, the 
subject
 
will be randomized by 
[CONTACT_612647]
C/IWRS system. The site should follow the instructions provided in 
the Study Reference Manual)
/eCRF Completion 
Guidelines
 
to enter appropriate 
subject
 
data into 
the eCRF and randomize the 
subject
. A study drug bottle number will be assigned to the 
subject
 
based on the predetermined randomization by [CONTACT_97937]/IWRS system. The
 
designated
 
site
 
personnel
 
should 
supervise the 
administ
ration of
 
the first dose of study drug 
by 
[CONTACT_612648]
s
 
and 
diary to the 
subject
.
 
T
he second dose 
will 
be administered at home.
 
 
A subject who fails to qualify for the study 
on POD1
 
will not be rescreened.
 
 
Note that 
the use of IOP
-
lowering medications or aqueous release procedures are not allowed on 
POD1. 
 
Study drug dosing/administration 
procedures 
including handling bottle replacement, diary/dosing 
compliance and the list of treatments are presented in 
Section 
5.1.[ADDRESS_812216]
s are reminded to 
bring 
the 
diary to each clinic visit in order for site staff to review dosing compliance.
 
6.2.4
 
Visit 3 (
POD
4
 
± 1
) 
and 
Visit 
4
 
(POD
8
 
± 1
)
 
All assessments will
 
be performed as shown in the Schedule of Events (
Table 
1
). 
 
O
cular assessments will be performed only 
o
n the operated, study eye at 
Visit 3 (
POD
4)
 
and
 
Visit 4 (POD
8
)
.
 
6.2.[ADDRESS_812217]
 
on POD14 (no 
specific 
window) 
to remind 
the subject
 
not to take study drug on POD
[ADDRESS_812218] 
and to bring the 
bottle of study drug and diary back to the clinical site at 
Visit 
5
 
(
POD15
)
. Site personnel will 
contact [CONTACT_612649]
g the 
subject
’s preferred reliable method of communication, 
e.g.,
 
telephone call, cell phone text or email. 
T
he site staff must 
make an effort
 
to ensure that the 
subject
 
receives and acknowledges the receipt of the message.
 
Method of contact [CONTACT_612650].
 
Clinical Study Protocol:  CPN
-
301
 
Formosa Pharmaceuticals, Inc.
 
APP13007
 
 
Version 1.
3 
(Amendment 1)
 
CONFIDENTIAL
 
Page 
[ADDRESS_812219] be recorded in the source 
documents
 
and eCRF
. Further assessment of any reported AEs may require an Unscheduled Visit 
on POD
14 
i
f medically significant or they may be assessed, as appropriate, 
at
 
Visit 
5
 
(POD15)
.
 
6.2.6
 
Visit 5 (
POD15
 
+ 1
)
 
All assessments will be performed as shown in the Schedule of Events (
Table 
1
). 
 
O
cular assessments 
will 
be performed on
ly on
 
the operated, study eye. 
 
Study drug bottle and final diaries 
will
 
be collected at this visit.
 
6.2.7
 
Visit 6 (
POD22
 
± 2
)
 
Th
is is the 
final 
visit for t
he subjects. 
 
All assessments will be performed as shown in the Schedule of Events (
Table 
1
). 
 
O
cular assessments 
will
 
be performed on both eyes. 
 
Subject
s with ongoing AEs or SAEs should be handled as discussed in 
Section 
8.0
. 
 
6.2.8
 
Early Termination
/Withdrawal
 
Subject
s who are terminat
ed
/withdrawn
 
from the study early
 
will have the Visit 
6
 
(POD22) 
assessments 
and a urine pregnancy test 
performed at the time of 
early 
termination, or as soon 
thereafter as possible. At 
an 
E
arly 
T
ermination
/Withdrawal
 
visit 
the ocular assessments are to be 
performed on both eyes.
 
Appendix A
 
describes the Early Termination
/Withdrawal
 
procedures that may be implemented 
because of the COVID
-
[ADDRESS_812220] be documented in the
 
Unscheduled Visit pages of the eCRF. Unscheduled visits may include, but are not limited to, 
reporting and/or follow
-
up of AEs/SAEs, changes in concomitant medications, follow
-
up of 
subject
s receiving rescue or IOP
-
lowering medications or ophthalmic asses
sments as deemed 
appropriate by [CONTACT_737]. 
 
6.2.[ADDRESS_812221]
s who 
are rescued as discussed
 
in 
Section 
9.4
 
will
 
discontinue study drug
 
and receive 
rescue medication. 
 
Clinical Study Protocol:  CPN
-
301
 
Formosa Pharmaceuticals, Inc.
 
APP13007
 
 
Version 1.
3 
(Amendment 1)
 
CONFIDENTIAL
 
Page 
[ADDRESS_812222]
s who are rescued in the study 
until 
they complete the 
Visit 6 (POD22) 
asse
ssments (
Table 
1
).
 
6.[ADDRESS_812223] Early Termination (Withdrawal)
 
Any 
subject
 
who wishes to voluntarily discontinue study drug or withdraw from participation in 
the study for any reason is entitled to do so without ob
ligation
.
 
If a 
subject
 
request
s
 
to 
discontinue the study drug, the 
subject
 
will be withdrawn from the study as an 
Early T
ermination 
(see 
Section 
6.2.7
).
 
The Investig
ator may discontinue any 
subject
 
from study drug or from study participation, if 
deemed necessary at any time during the study for any reason including, but not limited to:
 

 
T
he investigator considers that the subject requires alternative medication
 
that is
 
incompatible with further continuation of the study drug or participation in the study
. 
 

 
Occurrence of any medical condition or circumstance that exposes the subject to substantial 
risk and/or does not allow the subject to adhere to the requirements of th
e protocol.
 

 
Any SAE, clinically significant AE, severe laboratory abnormality, intercurrent illness, or 
other medical condition that indicates to the Investigator that continued participation in the 
study is not in the best interest of the subject or that 
continued participation could affect 
study objectives.
 

 
Any woman who 
reports 
becom
ing
 
pregnant while participating in the study. Information on 
the pregnancy and outcome will be requested by [CONTACT_737]. 
 

 
Subject’s continued failure to comply with
 
pro
tocol requirements or study
-
related procedures 
after being instructed on 
the 
correct 
requirements or 
procedures by [CONTACT_612651].
 

 
Termination of the study by [CONTACT_1034], FDA, or other regulatory authority.
 
 
In the event that 
early 
termination
/withdrawal
 
of a randomized 
subject
 
is necessary (‘withdrawn’ 
subject
), the Investigator should make every attempt to 
complete 
the 
Visit 
[ADDRESS_812224] 
as soon as possible
 
(
Table 
1
).
 
Note: the 
Visit 6 
ocular 
assessments need to be performed on both eyes. 
 
The reason for 
early 
termination
/withdrawal
 
of a 
subject
 
should be recorded in the source 
document
s
 
and entered in the eCRF.
 
Subject
s who are
 
terminated early from the study will not be replaced.
 
Clinical Study Protocol:  CPN
-
301
 
Formosa Pharmaceuticals, Inc.
 
APP13007
 
 
Version 1.
3 
(Amendment 1)
 
CONFIDENTIAL
 
Page 
[ADDRESS_812225]
.
 
Clinical Study Protocol:  CPN
-
301
 
Formosa Pharmaceuticals, Inc.
 
APP13007
 
 
Version 1.
3 
(Amendment 1)
 
CONFIDENTIAL
 
Page 
[ADDRESS_812226]
s’ 
demographic information will be collected and recorded
 
in the eCRF
. A complete 
systemic and ocular medical 
and surgical 
history will be taken at screening
, and abbreviated 
assessment
 
will be taken at the 
subsequent
 
visits.
 
7.[ADDRESS_812227]
y
 
to the Study (Operated) Eye Only
.
 

 
Slit Lamp Biomicroscopy
 
assessment of 
(i) ACC
 
count and 
(ii) 
ACF grade
 
using a 5 point 
scale (0
-
4)
.
 

 
Subject
-
Rated Ocular Pain Assessment (0
-
4
 
Scale)
 

 
Number of 
subjects who are rescued
 

 
B
est corrected visual acuity by [CONTACT_21173][INVESTIGATOR_612621]
 
 
7.2.2
 
P
rocedures for 
Assessment of 
E
fficacy 
E
nd
p
oints
 
[IP_ADDRESS]
 
Anterior Chamber Cell Count 
and
 
Anterior Chamber Flare 
 
The biomicroscopy examination will be performed with the s
lit lamp using a slit
-
beam. The 
Investigator should use their usual examination technique. Anterior chamber cells should be 
counted using the high light intensity level and the high magnification (Haag
-
Streit 16 X or 
comparable), with the slit beam set at 
an oblique angle, and the height and width of the beam set 
to 1.0 X 1.0 mm.
 
ACF will be 
graded as shown below
:
 
Grade
 
Description
 
0
 
None
 
1
 
Faint
 
2
 
Moderate (iris and lens details clear)
 
3
 
Marked (iris and lens details hazy)
 
4
 
Intense (fibrin or 
plastic aqueous)
 
Clinical Study Protocol:  CPN
-
301
 
Formosa Pharmaceuticals, Inc.
 
APP13007
 
 
Version 1.
3 
(Amendment 1)
 
CONFIDENTIAL
 
Page 
62
 
of 
89
 
[IP_ADDRESS]
 
Subject
-
Rated Ocular Pain Assessment
 
Ocular pain is defined as throbbing, or aching, and 
will be
 
graded by 
[CONTACT_612652] a [ADDRESS_812228]
s will be required to 
subjective
ly rate their pain in 
the study eye 
before any other ocular assessments are performed
. 
 
Ocular Pain will be graded a shown below
:
 
Grade
 
Description
 
0
 
No
ne: No
 
pain.
 
1
 
Minimal: Presence of 
minimal throbbing or aching pain (expected 
following cataract surgery)
.
 
2
 
Mild: Presence of mild throbbing or aching pain, easily tolerated.
 
3
 
Moderate: Presence of moderate throbbing or aching pain leading to the 
desire to use an analgesic.
 
4
 
Severe: 
Presence of severe throbbing or aching pain that is not tolerable
 
 
[IP_ADDRESS]
 
B
est 
Corrected Visual Acuity
 
The assessment of best corrected visual acuity in the study (operated) eye will be performed as 
described in 
Section 
[IP_ADDRESS]
.
 
7.3
 
Safety Assessments
 
The safety 
assessments are applied to 
both eyes
 
at 
Visit 1 (
Screening
) and Visit 6 (POD22) 
or 
E
arly 
T
ermination
/Withdrawal
 
or
 
to
 
the 
Study (
o
perated) 
eye
 
only
 
at Visit 2 th
rough Visit 5. 
(
Table 
1
 
Schedule of Events)
. The safety assessments in 
Table 
[ADDRESS_812229] of 
Safety 
A
ssessment
s 
 

 
AEs
 

 
ETDRS Assessment of Best Corrected Visual Acuity by [CONTACT_25715][INVESTIGATOR_202324]
 

 
Slit Lamp Biomicroscopy assessment of the following
 
signs of inflammation: corneal edema, 
ciliary flush, bulbar conjunctival injection
. The assessments in the non
-
study eye will include 
an assessment of the lens
 
 

 
IOP Measurement 
using 
Goldmann applanation tonometry
 

 
Dilated Ophthalmoscopy
 
assessment of the 
vitreous, retina, macula, choroid, and optic nerve 
with cup/disc ratio
, and an assessment of the presence and severity of a cataract if present in 
the non
-
study eye
 
Clinical Study Protocol:  CPN
-
301
 
Formosa Pharmaceuticals, Inc.
 
APP13007
 
 
Version 1.
3 
(Amendment 1)
 
CONFIDENTIAL
 
Page 
63
 
of 
89
 
[IP_ADDRESS]
 
A
ssessment of 
A
dverse 
E
vents
 
All AEs spontaneously reported by [CONTACT_612653], physical examination or other diagnostic procedures will 
be recorded in the source document and on the appropriate pages of the eCRF. Any clinically 
relevant deterioration in a cl
inical finding is considered an AE and must be recorded. When 
possible, signs and symptoms indicating a common underlying pathology should be noted as one 
(1) comprehensive event. Any pre
-
existing medical condition that worsens after administration 
of stud
y drug will also be considered as an AE. 
 
Ocular complaints associated with and expected as a result of the surgery, that are not recorded 
as AEs in the eCRFs will be recorded in the source documents. An o
cular complaint 
will
 
be 
recorded in the eCRF 
as AE 
when 
the complaint is outside the normal limits for cataract surgery 
or is associated with clinical sequelae (i.e., adverse slit lamp examination finding). 
 
See 
Section 
8.[ADDRESS_812230] surgery or study drug.
 
[IP_ADDRESS]
 
ETDRS Best Corrected Visual Acuity Measurement by [CONTACT_25715][INVESTIGATOR_612622] a 
preferred (but not required) distance of [ADDRESS_812231]
 
is unable to correctly read any letters on that line. 
 
The ETDRS Acuity Log Score was calculated as follows:
 
1.
 
Determine the last row where the subject can corre
ctly identify at least one (1) letter in 
that row. This is the Base Logarithm of the Minimum Angle of Resolution (logMAR) 
line.
 
2.
 
Determine the log score for the Base logMAR line.
 
3.
 
Add 0.02 (T=0.02) log units for every letter that is incorrectly identified up
 
to and 
including the Base logMAR line.
 
The results will be recorded in the source documentation and the eCRF.
 
Clinical Study Protocol:  CPN
-
301
 
Formosa Pharmaceuticals, Inc.
 
APP13007
 
 
Version 1.
3 
(Amendment 1)
 
CONFIDENTIAL
 
Page 
64
 
of 
89
 
[IP_ADDRESS]
 
Slit Lamp Biomicro
s
copy
 
In addition to the assessment of 
ACC
 
and 
ACF (
Section 
[IP_ADDRESS]
)
, the following 
safety 
parameters 
will be evaluated 
at Visits 1 through 6 
as 
indicated
 
in 
Table 
1
 
using the following scales during 
the slit lamp exam
ination
:
 
Bulbar Conjunctival Injection
 
Grade
 
Description
 
0
 
Absent
 
1
 
Mild
 
2
 
Moderate
 
3
 
Severe
 
 
Sclera 
-
 
Ciliary Flush
 
Grade
 
Description
 
0
 
Absent
 
1
 
Mild
 
2
 
Moderate
 
3
 
Severe
 
 
Corneal Edema
 
Grade
 
Description
 
0
 
Absent
 
1
 
Mild
 
2
 
Moderate
 
3
 
Severe
 
 
The lens in the non
-
study eye will be classified as phakic, pseudo
-
phakic or non
-
phakic. 
 
7.3.2
 
IOP Measurement
 
IOP measurements will be performed utilizing Goldmann
 
applanation tonometry according to 
the Investigator’s standard procedure. All pressures will be recorded in mmHg. IOP assessments 
will be performed at 
Visits 1 
(Screening) 
through 
Visit 
6
 
(POD22) or Early 
Termination
/Withdrawal
 
as indicated in 
Table 
1
.
 
Clinical Study Protocol:  CPN
-
301
 
Formosa Pharmaceuticals, Inc.
 
APP13007
 
 
Version 1.
3 
(Amendment 1)
 
CONFIDENTIAL
 
Page 
65
 
of 
89
 
7.3.3
 
Dilated Ophthalmoscopy
 
A dilated fundus examination will be performed according to the Investigator’s standard 
technique 
at 
the 
Visits
 
indicated in 
Ta
ble 
1
. The Investigator should evaluate the vitreous, retina, 
macula, choroid, and optic nerve with cup/disc ratio and will note normal/abnormal findings.
 
If a 
cataract is present in the non
-
study eye, the Investigator will make an assessment of its location 
and severity
 
as described below
.
 
The Investigator will determine whether or not abnormalities observed at 
Visit 1 (
Screening
)
 
would exclude a 
subject
 
from study participation. 
 
If a subject had an abnormality in the study
 
eye
 
or non
-
study eye at Visit 1 (Screening), the 
Investigator should make an assessment whether there has been a change at Visit 6 (POD22) or 
at Early Termination
/Withdrawal
 
and recor
d this in the source document and eCRF. It is 
recommended that the Investigator refer to the documentation at Visit 1 (Screening) when 
making the assessment of a change in status.
 
Grading a 
Cataract 
in 
the Non
-
Study Eye
 
F
or subjects with 
a
 
natural 
lens 
in 
the non
-
study eye, when present, a 
cataract 
will be assessed 
(a)
 
by [CONTACT_157478] 
-
 
Nuclear, Cortical, and Posterior Subcapsular
,
 
and 
(b) 
by 
[CONTACT_926] (
minimal, 
mild, moderate or severe). 
Appendix B
 
provides a g
uidance 
that may be used to 
grad
e
 
the 
severity of a nuclear, cortical or posterior subcapsular cataract in the non
-
study eye.
 
If a subject had a cataract in the non
-
study eye at Visit 1 (Screening), the Investigator should 
make an assessment wh
ether there has been a change in the size or composition of the cataract at 
Visit 6 (POD22) or at Early Termination/Withdrawal and record this in the source document and 
eCRF. It is recommended that (i) the cataract grading is performed by [CONTACT_612654] 6 (POD22) or at Early Termination/Withdrawal, and (ii) the Investigator 
refers to the documentation of the non
-
study eye at Visit 1 (Screening) when making the 
assessment of change in the lens status.
 
 
Clinical Study Protocol:  CPN
-
301
 
Formosa Pharmaceuticals, Inc.
 
APP13007
 
 
Version 1.
3 
(Amendment 1)
 
CONFIDENTIAL
 
Page 
66
 
of 
89
 
 
A
DVERSE 
E
VENTS
 
8.1
 
Definition of Adverse Events (AE
s
)
 
Adverse event means any 
untoward medical occurrence in a 
subject
 
or clinical investigation 
subject
 
administered a pharmaceutical product and
 
which does not necessarily have a causal 
relationship with this treatment (21CFR312.32 (a); ICF E6 Section 1). An AE can therefore be 
any unfavorable sign and unintended sign (including an abnormal laboratory finding), symptom, 
or disease temporally assoc
iated with the use of a medicinal (investigational) product, whether or 
not related to the medicinal (investigational) product.
 
In addition to the considerations in
 
Sections 
8.2
 
to
 
8.4
, AEs
 
will be re
ported
 
in the source 
document 
from the time of signature [CONTACT_612676] 
8.1.1
 
and 
Section 
8.1.2
.
 
 
8.1.1
 
Subjects who are 
Randomized
 

 
An AE 
related to
 
catar
act surgery will be recorded in 
the 
Surgical AE log 
table
 
in the
 
source 
documents 
and
 
in the eCRF
.
 

 
AEs occurring prior to study drug administration will be recorded in the source documents 
only.
 

 
AEs 
occurring from the start of study drug administration 
wil
l be reported in the source 
documents and eCRF.
 

 
Rescued subjects are considered to be treatment failures, and 
being 
rescue
d
 
itself is not 
considered 
to be 
an AE.
 

 
Adverse events occurring in rescued subjects 
will
 
be reported in the 
source documents and 
eC
R
F. 
 

 
An IOP > 30 mmHg 
after
 
Randomization 
will
 
be reported as an AE
 
i
n 
the source documents 
and 
eCRF
.
 

 
An IOP 
≥ 
21 mmHg 
AND
 
an IOP increase 
>
 
10 mmHg from pre
-
dose baseline 
will
 
be 
reported as an AE
 
i
n 
the source documents and 
eCRF
.
 

 
S
erious Adverse Events will be collected from the time of signature [CONTACT_612677].
 
 
The term “severe” is used to describe the intensity of an AE; the event itself could be of 
relatively minor clin
ical significance (e.g., ‘severe’ headache). This is not the same as “serious”. 
Seriousness of AEs is based on the outcome of an AE and usually associated with events that 
pose a threat to a 
subject
’s life or functioning.
 
Clinical Study Protocol:  CPN
-
301
 
Formosa Pharmaceuticals, Inc.
 
APP13007
 
 
Version 1.
3 
(Amendment 1)
 
CONFIDENTIAL
 
Page 
67
 
of 
89
 
A Treatment Emergent Adverse Event
 
(TEAE) will be defined as any AE that occurs 
from the 
start of 
study drug 
administration through 
Visit 6 (POD22)
. 
 
8.1.2
 
Subjects who are 
Not Eligible for R
a
ndomization (
Screen Failures
)
 

 
AEs will be reported in the source documents only
 

 
Serious Adverse Events w
ill be 
collected from the time of signature [CONTACT_612678]
 
 
8.2
 
Definition of Serious Adverse Events
 
(SAE
s
)
 
An AE is considered "serious" if the event results in any of the following outcomes: 
 

 
death, 
 

 
a life
-
threatening adverse event (i.e. the 
subject
 
is, in the view of the investigator, at 
immediate risk of death from the AE as it occurs), 
 

 
s
ubject
 
hospi[INVESTIGATOR_612623], 
 

 
a persistent or significant incapacity or substantial disruption of the ability to conduct normal 
life functions, or 
 

 
a congenital anomaly/birth defect. 
 
 
Important medical events that may not result in death, but may be life
-
threatening, or require 
hospit
alization may be considered serious when, based upon appropriate medical judgment, they 
may jeopardize the participant and may require medical or surgical intervention to prevent one of 
the outcomes listed in this definition. Examples of such medical event
s include allergic 
bronchospasm requiring intensive treatment in an emergency room or at home, blood dyscrasias 
or conv
ulsions that do not result in 
subject
 
hospi[INVESTIGATOR_059], or the development of drug 
dependency or drug abuse.
 
A s
erious
 
and 
unexpected s
usp
ected
 
adverse reaction (S[LOCATION_003]R) is defined as a serious adverse 
reaction 
or suspected serious adverse reaction 
that is not listed in the 
APP13007
 
Investigator’s 
Brochure or is not listed at the specificity or severity that has been observed, or that is ment
ioned 
in the
 
APP13007
 
Investigator’s Brochure as occurring with a class of drugs or as anticipated 
from the pharmacological properties of the study drug, but is not specifically mentioned as 
occurring with the particular drug under 
investigation (See 
Secti
on 
8.7.2
).
 
Clinical Study Protocol:  CPN
-
301
 
Formosa Pharmaceuticals, Inc.
 
APP13007
 
 
Version 1.
3 
(Amendment 1)
 
CONFIDENTIAL
 
Page 
[ADDRESS_812232] grade documented.
 
Table 
5
:
 
Definitions of AE Severity
 
Mild
 
Events require minimal or no treatment and do not interfere with the 
participant’s daily activi
ties.
 
Moderate
 
Events result in a low level of inconvenience or concern with the 
therapeutic measures. Moderate events may cause some interference with 
functioning.
 
Severe
 
Events interrupt a participant’s usual daily activity and may require 
systemic drug therapy or other treatment. Severe events are usually 
potentially life
-
threatening or incapacitating. Of note, the term “severe” 
does not necessarily equate to “serious”.
 
 
8.3.2
 
Relationship to Ocular Surgical Procedure o
r
 
Study Drug
 
Determination of the relationship (if any) between the AE and the study drug will be made using 
the guidelines presented in 
Table 
6
 
and 
Table 
7
.
 
Table 
6
:
 
Guidelines for Determining the Relationship (if any) between an Adverse 
Event and the Ocular Surgical Procedure
 
Related
 
This causal relationship is 
assigned if the AE starts at a reasonable time during 
or after the surgical intervention and could reasonably be explained by [CONTACT_612655].
 
Not 
Related
 
This causal relationship is assigned when the time association or the 
subject
’s 
clinical state is such that the surgical intervention was not likely to have had an 
association with the observed AE.
 
 
Clinical Study Protocol:  CPN
-
301
 
Formosa Pharmaceuticals, Inc.
 
APP13007
 
 
Version 1.
3 
(Amendment 1)
 
CONFIDENTIAL
 
Page 
69
 
of 
89
 
Table 
7
:
 
Guidelines for Determin
ing the Relationship (if any) between an Adverse 
Event and the Study Drug
 
Definite
 
This causal relationship is assigned if the AE starts a reasonable time after the 
administration of study drug, stops/improves when the study drug is stopped, 
and could 
reasonably be explained by [CONTACT_200503].
 
Probable
 
This causal relationship is assigned when the AE starts a reasonable time after 
the administration of study drug, stops/improves when the study drug is 
stopped, and could not be 
reasonably explained by [CONTACT_126026]
’s clinical state.
 
Possible
 
This causal relationship is assigned when the AE starts a reasonable time after 
the administration of study drug, but could be produced by [CONTACT_1560]
’s clinical 
state
 
or other modes of therapy administered to the 
subject
.
 
Not Related
 
This causal relationship is assigned when the time association or the 
subject
’s 
clinical state is such that the study drug was not likely to have had an 
association with the observed AE.
 
 
The attributability (relatedness) of an AE to the surgical procedure or to the study drug will be 
reported in the source documents and in the eCRF as described in 
Section 
8.1.1
 
and
 
Section 
8.1.2
. 
 
8.3.3
 
Expectedness
 
An AE or a suspected adverse 
reaction
 
(SAR) is considered “unexpected” if it is not listed in the 
APP13007
 
Investigator’s Brochure or is not listed at the specificity or severity that has been 
observed. Expected events for APP13007 administration include those events described in the 
APP13007 Investigator’s Brochure.
 
8.3.[ADDRESS_812233]
s will be permitted to restart study drug if there is a temporary interruption of study drug 
dosing not more than 1 day due to an AE. 
 
Decrease in the dosing freque
ncy
 
or dosing duration
 
of 
the 
study drug is not allowed in this 
study.
 
Clinical Study Protocol:  CPN
-
301
 
Formosa Pharmaceuticals, Inc.
 
APP13007
 
 
Version 1.
3 
(Amendment 1)
 
CONFIDENTIAL
 
Page 
70
 
of 
89
 
8.3.5
 
A
dverse 
E
vent 
O
utcome
 
If an AE occurs, the Investigator will institute support and/or treatment as deemed 
appropriate.
 
The outcome of the adverse event will be categorized as follows:
 

 
R
esolved
 

 
Resolved with sequelae
 

 
Ongoing
 

 
Death
 

 
Unknown
 
 
The Investigator should make every attempt to follow SAEs to resolution.
 
8.[ADDRESS_812234]
’s final study visit, the 
subject
 
will 
still be 
released
 
from the study, but an effort will be made to follow up until the AE is resolved 
or stabilized, the 
subject
 
is lost to follow
-
up, or there 
is some other resolution of the event. The 
Investigator should make every attempt to follow all SAEs to resolution. 
 
8.5
 
Overdose/Under
-
dose for Assessment of Compliance
 
8.5.[ADDRESS_812235]
 
and 
reviewed by [CONTACT_261238]. 
 
The following will be classified as a
n overdose event and a protocol deviation
 
(
further explained 
in Note below
)
:
 

 
S
ubject
 
instill
s >
 
2
 
do
ses
 
of study drug 
(each dose = 1 drop) 
into the study eye 
on 
2
 
cons
ecutive days
.
 
 
 
Note:
  
(i) 
As described in 
Section 
5.1.[ADDRESS_812236] drop
 
or more
 
into the conjunctival 
sac, no matter if the 
previous 
drop
s were
 
missed, this will be 
considered to be 
a protocol 
Clinical Study Protocol:  CPN
-
301
 
Formosa Pharmaceuticals, Inc.
 
APP13007
 
 
Version 1.
3 
(Amendment 1)
 
CONFIDENTIAL
 
Page 
71
 
of 
89
 
deviation
; (ii) the importance of the protocol deviation (major/minor) will be determined by [CONTACT_612656].
 
8.5.[ADDRESS_812237]
 
has missed
 
both 
of the 
doses
 
o
n 
2 
or more 
consecutive days
.
 
The importance of the protocol deviation (major/minor) will be determine by [CONTACT_612657].
 
8.[ADDRESS_812238] on POD1 prior to randomization
 
(and agree to
 
abstain from sexual 
activity or use an effective method of contraception)
. Therefore, no pregnancies should occur. 
A 
urine pregnancy test will also be 
performed at Visit 5 (POD15) or Early Termination
/Withdrawal
 
visit
 
prior to POD15
.  
If there is an unexpected pregnancy, it will be handled on a case
-
by
-
case 
basis by [CONTACT_612658].
 
Additiona
lly, the Investigator should report the information to the Sponsor 
in a Pregnancy
-
specific CRF 
as per the procedures to be followed for an SAE. Although a pregnancy itself is not 
an SAE, it has potentially serious consequences in 
subject
s exposed to invest
igational drugs that 
can result in an SAE.
 
The pregnancy and follow
-
up of the pregnancy must be reported on the appropriate pregnancy 
CRF and Pregnancy Reporting Form. The expected date of delivery or expected date of the end 
of the pregnancy, last menstru
ation, estimated fertility date, pregnancy result and neonatal data 
etc., should be included in this information.
 
The investigator will follow the medical status of the mother, as well as the fetus, as if the 
pregnancy is an SAE and will report the outcome
 
to the Sponsor. Follow
-
up visits must continue 
until the end of the pregnancy, even if that lasts beyond the end of the study.
 
When the outcome of the pregnancy falls under the criteria for SAEs 
(
spontaneous abortion, 
induced abortion, stillbirth, death o
f newborn, congenital anomaly 
[
includin
g anomaly in a 
miscarried fetus])
, the investigator should respond in accordance with the report procedure for 
SAEs. Additional information regarding the outcomes of a pregnancy which are categorized as 
an SAE is ment
ioned below:
 

 
"Spontaneous abortion" includes abortion and missed abortion.
 

 
Death of an infant within 1 month after birth should be reported as an SAE regardless of its 
relationship with the study drug.
 
Clinical Study Protocol:  CPN
-
301
 
Formosa Pharmaceuticals, Inc.
 
APP13007
 
 
Version 1.
3 
(Amendment 1)
 
CONFIDENTIAL
 
Page 
72
 
of 
89
 

 
If an infant dies more than 1 month after the birth, i
t should be reported if a relationship 
between the death and intrauterine exposure to the study drug is judged as "possible" by [CONTACT_1275].
 

 
In the case of a delivery of a living newborn, the "normality" of the infant is evaluated at 
birth.
 

 
"Normality
" of a miscarried fetus is evaluated by [CONTACT_612659] a congenital anomaly are obtained prior to miscarriage.
 
8.7
 
Serious Adverse Event Reporting
 
8.7.1
 
R
eporting 
R
equirements
 
It is the responsibility of the Investigators or th
eir designees to report any event of this nature to 
the Sponsor or a designee within 24 hours of the event being brought to the Investigators’ or 
their staffs’ attention. It is also the responsibility of the Investigator to report all SAEs reported at 
thei
r site to the IRB, as required. The Investigator should make every attempt to follow all SAEs 
to resolution. 
 
All SAEs have to be reported
 
on a separate SAE Report Form
, whether or not considered 
causally related to the 
study
 
drug, or to the study procedur
e(s). 
All SAEs will be recorded in the 
eCRF
. SAEs will be recorded from the time 
the 
informed consent
 
form is signed
. 
 
The Sponsor will be responsible for reporting all SAEs to regulatory authorities and 
the 
Investigator is responsible for reporting all SA
Es to the 
IRB
 
(see NOTE below) in accordance 
with I
RB guidelines
 
and 
FDA
 
regulations. As soon as the Investigator is aware of a potential 
SAE he/she should contact 
 
 
[CONTACT_612660] [ADDRESS_812239]
 
number, birth date, description of the SAE and a preliminary 
assessment of causality
. 
 
For fatal or life
-
threatening adverse events where important or relevant information is missing, 
active follow
-
up is undertaken immediately. Investigators or other site personnel inform the 
Study Medical Monitor, the Sponsor, and the CRO for Study Manag
ement and Monitoring of 
any follow
-
up information on a previously reported SAE immediately but no later than within 
24
 
hours of when the Investigator becomes aware of it. The Study Medical Monitor or Sponsor 
Medical Monitor will advise the Investigator/stu
dy site personnel how to proceed.
 
The 
Investigator will immediately follow
-
up events deemed by [CONTACT_612661] (S[LOCATION_003]Rs) or possible S[LOCATION_003]R events needing 
immediate follow
-
up in order to meet the 15 calend
ar day reporting requirements.
 

Clinical Study Protocol:  CPN
-
301
 
Formosa Pharmaceuticals, Inc.
 
APP13007
 
 
Version 1.
3 
(Amendment 1)
 
CONFIDENTIAL
 
Page 
73
 
of 
89
 
The SAE reporting procedures are detailed in the study
-
specific Safety Management Plan. This 
plan is an agreement between the Sponsor, the CRO for Study Management and Monitoring and 
.
 
NOTE:
 
If an unexpected SAE occurs at any one site that is determined to be related, probably 
related or possibly related to study drug, all study sites will be notified by [CONTACT_612662]. 
 
8.7.2
 
R
eporting of 
S
erious
 
and 
U
nexpected 
S
uspected
 
A
dverse 
R
eactions (
S[LOCATION_003]R
S
)
 
A s
erious s
uspected adverse reaction is any serious adverse event for which there is a reasonable 
possibility that the 
study drug
 
caused the adverse event. A serio
us adverse reaction is considered 
"unexpected" 
(serious and unexpected suspected adverse reaction; S[LOCATION_003]R) 
if it is not listed in 
the APP13007 Investigator’s Brochure or is not listed at the specificity or severity that has been 
observed. 
 
S[LOCATION_003]Rs with an ou
tcome of death or are life threatening must be reported to the relevant 
Regulatory Authorities within [ADDRESS_812240] be submitted within 
15calendar days. The S[LOCATION_003]R reporting procedures are detailed in the study Safety Management 
Pla
n. This plan is an agreement between the Sponsor, the CRO for Study Management and 
Monitoring and 
Synergy Research Pharmacovigilance
. 
 
NOTE:
 
The Sponsor will notify the 
U.S. Food and Drug Administration (FDA) 
and all 
participating site Investigators of any
 
S[LOCATION_003]Rs (via the CRO for Study Management and 
Monitoring) on an expedited basis and in accordance with applicable regulations. In addition the 
sponsor is responsible for informing all Investigators in all ongoing studies involving the study 
drug about all 
S[LOCATION_003]Rs. 
 
Medical and administrative data related to I
ndividual 
C
ase 
S
afety 
R
eport
s which qualify for 
expedited and periodic reporting, should be provided in compliance with U.S. F
DA
 
Code of 
Federal Regulations (CFR) 21, 312.32.
 
It is the responsibility of the Investigator to promptly notify the IRB and other appropriate 
institutional regulatory bodies of all unexpected serious adverse reactions involving risk to 
human 
subject
s as per
 
their applicable requirements.
 

Clinical Study Protocol:  CPN
-
301
 
Formosa Pharmaceuticals, Inc.
 
APP13007
 
 
Version 1.
3 
(Amendment 1)
 
CONFIDENTIAL
 
Page 
[ADDRESS_812241]
 
[IP_ADDRESS]
 
Lack of 
E
fficacy (See 
Section 
9.4
)
 
T
he Investigator should consider whether to stop the study drug because of lack of efficacy and 
rescue the subject with alternative therapy (see 
Section 
9.4
).
 
 
Rescued subjects shall continue in the study and be assessed at each subsequent scheduled visit 
until Visit 6 (POD22).
 
The study drug will be stopped as indicated in 
Section
 
9.4.2
.
 
[IP_ADDRESS]
 
Elevated Intraocular Pressure
 
(See 
Section 
9.5
)
 
The Investigator shou
ld consider whether to stop the study drug because of an elevation of IOP. 
The study drug may or may not be continued as indicated in 
Section 
9.5.2
.
 
[IP_ADDRESS]
 
Deleterious Effec
ts of the Study Drug
 
The investigator may stop the study drug and 
withdraw the 
subject
 
if in their opi[INVESTIGATOR_612624] a deleterious effect on the 
subject
’s
 
health or wellbeing.
 
The investigator should 
make an effort to follow up the subject until the deleterious effect is resolved.
 
[IP_ADDRESS]
 
Lack of Compliance
 
The investigator may stop the study drug and withdraw the subject if in their opi[INVESTIGATOR_612625], including, but not limited to, dosing of the study drug.
 
9.1.2
 
Study 
Termination
 
 

 
The study can be stopped at any time if deemed necessary by [CONTACT_37755]
,
 
in consultation with the Study Medical Monitor
,
 
due to safety concerns. 
S
afety will
 
be 
monitored on an ongoing basis via periodic masked review of AEs and other safety 
endpoints. 
 
O
 
I
f it is observed that visual acuity 
worsens by 
2 lines 
(Base LogMAR change of 0.2 using 
ETDRS chart
) 
at 
Visit 6 (POD22) 
in the treated study eye as compared t
o 
Visit 2 
(
POD1
)
, in [ADDRESS_812242]
s in the study until a comprehensive evaluation can be performed
,
 
and, if 
possible, a cause is identified. 
 

 
Safety assessments will be performed throughout the course of the study. The APP13007 
Investigator’s Brochur
e, Section 
1.4.1
 
and the Risk Mitigation plan in
 
Table 
2
 
provide 
guidance for the Investigator on potential anticipated 
AE
s that may occur. Any potential 
Clinical Study Protocol:  CPN
-
301
 
Formosa Pharmaceuticals, Inc.
 
APP13007
 
 
Version 1.
3 
(Amendment 1)
 
CONFIDENTIAL
 
Page 
75
 
of 
89
 
important 
safety issues that arise will be reviewed by [CONTACT_612663]
l Monitor
,
 
in 
consultation with the Sponsor Medical Monitor
,
 
to identify the appropriate course of action. 
 

 
If the Sponsor elects to terminate the study for any reason, the Investigator will be 
responsible for notification of the IRB and will 
withhold further dosing of study drug.
 
9.[ADDRESS_812243] be recorded. 
 
Note:  Study drug bottle will be replaced if a bottle is lost or otherwise compromised before 
Visit 
5 (
POD15
)
 
(see
 
Section 
5.1.2
). 
 
9.[ADDRESS_812244]
 
not responding to the study drug 
because of lack of efficacy 
at any time after 
randomization 
at Visit 
2
 
(
POD1
)
 
may be rescued and placed on an appropriate alternative 
therapy determined by [CONTACT_737]. 
 
In general, at any visit, a subject with worsening inflammation or showing no imp
rovement in 
degree of inflammation compared with the previous visit is eligible for rescue therapy at the 
discretion of the Investigator. However, t
he following guidance 
is 
provided 
to 
I
nvestigators 
for
 
consistency in the way 
subject
s are rescued: 
 
1.
 
Subject
s who, on examination of the anterior chamber, have one or more of the following 
quantitative 
criteria
 
should
 
be 
r
escued and discontinued from study drug dosing and placed 
on rescue mediation:
 
o
 
A
n increase 
of
 
ACC
 
count by > 15 cells from 
the 
Visit 
2
 
(
POD1
) 
pre
-
dose baseline.
 
o
 
A 
≥
 
2 grade increase in 
ACF
 
grade 
from 
the 
Visit 
2
 
(
POD1
) 
pre
-
dose
 
baseline. 
 
Clinical Study Protocol:  CPN
-
301
 
Formosa Pharmaceuticals, Inc.
 
APP13007
 
 
Version 1.
3 
(Amendment 1)
 
CONFIDENTIAL
 
Page 
[ADDRESS_812245] is rescued, 
the study drug 
should be discontinued 
and 
rescue 
mediation
 
started
:
 
o
 
Subjects who have pain and/or photophobia that does not improve
,
 
even when
 
there is
 
an 
improvement in ACC count and/or ACF grade
,
 
may be 
rescued 
at the discretion of the 
investigator.
 
o
 
Subjects who have pain and/or photophobia that worsen
s 
may
 
be rescued 
at the discretion 
of the investigator
.
 
Initiation of rescue medication is at the discretion of the Investigator
. 
However, i
t is 
recommended that the Investigator uses the above 
guidance
 
to determine when to 
rescue a
 
subject
. 
If the quantit
ative ACC count or ACF grade criteria are 
not
 
met, t
he Investigator 
should 
discuss the 
qualitative 
reason(s) for rescue w
ith the Study Medical Monitor
 
for consistency 
across the study
.
 
 
9.4.[ADDRESS_812246]
 
using the guidance 
provided in 
Section 
9.4.1
 
and the 
appropriate rescue medication to use
. All rescued subjects will 
stop 
study drug 
at the time of rescue
 
and will 
continue in the study through completion of the 
Visit 6 (POD22) assessments
 
(
Table 
1
).
 
If a s
ubject needs to be rescued at Visit 5 (POD15), the Visit 5 (POD15) assessments (
Table 
1
) 
should be completed before the subject is administered rescue medication.
 
Rescu
ed 
subject
s will be considered treatment failures, 
and
 
the need for rescue medication will 
not be considered as an AE. 
 
An 
AE
 
occurring at the time of rescue
 
will be recorded in the eCRF and 
will be followed by [CONTACT_612664] (whichever comes 
last). 
 
If a 
subject
 
is rescued, this event will be 
recorded 
in the eCRF
 
(not as an AE)
. Medications used 
for rescue will be recorded in 
the ConMeds section of the eCRF
, indicating that they were used 
for rescue
. 
 
9.5
 
Management
 
of Increased IOP
 
9.5.1
 
Criteria for Starting IOP
-
Lowering Medication
 
Investigators should use the following criteria to determine whether to start IOP
-
lowering 
medication: 
 
o
 
A
fter randomization, an IOP > 30 mmHg
 
in the study eye
 
Clinical Study Protocol:  CPN
-
301
 
Formosa Pharmaceuticals, Inc.
 
APP13007
 
 
Version 1.
3 
(Amendment 1)
 
CONFIDENTIAL
 
Page 
77
 
of 
89
 
o
 
After randomization, an IOP 
≥ 
21 mmHg 
AND
 
an increase of 
>
 
10 mmHg from 
the 
Visit 
2 (
POD1
) 
pre
-
dose baseline 
in the study eye 
(both
 
of these
 
criteria must be met)
 
Initiation of IOP
-
lowering 
medication is at the discretion of the Investigator even if n
either
 
of the 
above criteria are met, however, it is recommended that the Investigator uses these criteria to 
determine when to consider a 
subject
 
for IOP
-
lowering medication. 
 
9.5.2
 
Management
 
Investi
gator will use clinical judgment to determine the appropriate IOP
-
lowering medication to 
use and when to withdraw study drug and procedures, in consultation with the Study Medical 
Monitor.
 
 
It is important to note that prostaglandin
-
based 
IOP lowering 
medi
cations are prohibited in this 
study.
 

 
After randomization and start of study drug, if a 
subject
 
has an IOP > [ADDRESS_812247] may require assessment at an unscheduled visit at the 
investigator’s discretion.
 
o
 
If 
the 
IOP is < [ADDRESS_812248]
 
may continue on study drug. 
 
o
 
If at the next visit, the IOP remains > [ADDRESS_812249] should continue 
in the study and 
complete 
the assessments indicated in 
Table 
1
 
through Visit 6 (POD22). 
The Study Medical Monitor should 
discuss the persistent elevation of IOP with the 
Sponsor
 
Medical Monitor. 
 

 
After randomization and start of study drug, an IOP of 
≥ 
21 mmHg 
AND
 
an increase 
>
 
10
 
mmHg from the 
Visit 
2 
(
POD1
)
/pre
-
dose baseline (both criteria must be met) is 
considered clinic
ally significant and the Investigator should consider starting 
non
-
prostaglandin
-
based
 
IOP
-
lowering medication while continuing the study drug, with 
appropriate follow
-
up at the next planned visit or at an unscheduled visit. 
 
o
 
If the IOP reduction is 
satisf
actory at the next visit, the 
subject
 
may continue on study 
drug.
 
o
 
If 
the IOP 
reduction of IOP 
is not satisfactory 
at the next visit,
 
then the study drug may 
be discontinued and alternative IOP
-
lowering medication may be started, after 
consultation with the Study Medical Monitor. The subject should continue in the study 
and 
complete 
the assessments indicated in 
Table 
1
 
through Visit 6 (POD22). The Study 
Medical Monitor should discuss the persistent elevation of IOP with the Sponsor Medical 
Monitor
. 
 
Medications used for treating increased IOP will be recorded in the Concomitant Medications 
secti
on of the eCRF
, noting that they were used to reduce IOP
. 
 
Clinical Study Protocol:  CPN
-
301
 
Formosa Pharmaceuticals, Inc.
 
APP13007
 
 
Version 1.
3 
(Amendment 1)
 
CONFIDENTIAL
 
Page 
78
 
of 
89
 
 
S
TATISTICAL 
C
ONSIDERATIONS
 
10.1
 
Statistical Analytical Plan
 
The
 
Statistical Analysis Plan (SAP) 
will 
describ
e
 
the details of all efficacy and 
safety
 
analyses 
and 
will be finalized prior to database lock
.
 
10.2
 
Analysis Populations
 
The analysis populations are defined as follows:
 

 
Intent
-
to
-
Treat (ITT) Population: All 
subject
s who are randomized to study drug.
 
Following 
the ITT principle, subjects will be analyzed according to the treatment they are assigned to at 
randomization.
 

 
Per
-
protocol (PP) Population: All 
subject
s
 
in the ITT population who 
(i) received at last 
1
 
dose of study drug, (ii) 
do not 
have major
 
protocol deviations
 
that would impact the 
evaluation of efficacy and 
(iii) 
have at least 8
0% overall 
dosing
 
compliance. 
 

 
Safety Population: All randomized subjects who receive at least one dose of study drug. 
 
10.[ADDRESS_812250].
 
Subjects who are rescued at any time prior to Visit 5 (POD15) will be considered as treatment 
failures
 
for the primary efficacy endpoint
s and the relevant secondary efficacy endpoints
. For 
subjects who discontinue from the study prior to Visit 5 (POD15), the last observation carried 
forward (LOCF) approach will be used to impute missing data.
 
 
For 
continuous
 
secondary 
efficacy endpoints, t
he LOCF approach will also be used to impute the 
data 
at visits after 
subjects are 
rescued
.
 
The ACC count will be graded as shown below
:
 
 
Grade
 
0
 
1
 
2
 
3
 
4
 
ACC Count
 
0
 
c
e
l
l
 
1
-
5
 
c
e
lls
 
6
-
15
 
c
e
ll
s
 
16
-
30
 
c
e
ll
s
 
>
 
30
 
c
e
ll
s
 
Clinical Study Protocol:  CPN
-
301
 
Formosa Pharmaceuticals, Inc.
 
APP13007
 
 
Version 1.
3 
(Amendment 1)
 
CONFIDENTIAL
 
Page 
79
 
of 
89
 
[IP_ADDRESS]
 
Analyses of Primary Efficacy 
Endpoints:
 
The primary efficacy analyses to compare APP13007 against placebo will be conducted on the 
ITT population using the Pearson Chi
-
square statistic. Fixed sequence testing will be employed 
to maintain the 2
-
sided alpha = 0.05. The primary analyses 
will first test the difference 
between 
treatments 
in the proportion of 
subject
s with ACC count = 0 (Grade = 0) at POD8 (Visit 4) 
maintained through POD15 (Visit 5). If the test is statistically significant at the 2
-
sided alpha = 
0.[ADDRESS_812251]
s 
with Ocular Pain grade = 0 at POD4 (Visit 3) maintained through POD15 (Visit 5) will be tested 
at the two
-
sided alpha = 0.05 level. 
 
To confirm the robustness
 
of primary analysis results
, sensitivity analyse
s
, including using 
observed data 
from all subjects
,
 
will be performed
. 
The detailed 
sensitivity analyses
 
will be 
described 
in the SAP. 
 
[IP_ADDRESS]
 
Analyses of Secondary Efficacy Endpoints:
 
Mean 
change
-
from
-
baseline
 
in ACC Grade, ocular Pain Grade, ACF Grade and visual acuity at 
PODs 4, 8 and 15 will be analyzed using an analysis of covariance (ANCOVA). The ANCOVA 
model will include treatment 
as a
 
fixed effect and baseline as a covariate. The rest of secondary 
effica
cy endpoints will be analyzed using the same method described for the primary efficacy 
endpoints. 
 
10.3.[ADDRESS_812252]
s in the Safety Population. 
 
Adverse events will be coded using Medical Dictionar
y for Regulatory Activities 
(MedDRA) 
and 
classified
 
by [CONTACT_477816].
 
Adverse events will be summarized by 
[CONTACT_612665]
s
, number of 
subject
s reporting 
TE
AE
s
, ocular 
TE
AEs (affecting the study 
eye and/or the non
-
study eye an
d/or both eyes, when appropriate), 
non
-
ocular
 
TE
AEs, SAEs, 
serious
 
and 
unexpected s
uspected
 
adverse reaction (S[LOCATION_003]Rs), discontinuing study drug due to 
an AE, by [CONTACT_612666]/or ocular surgical procedure, and by [CONTACT_926]. 
 
The IOP data 
for
 
both eyes wil
l be summarized at screening,
 
V
isit 6
 
(POD22)
/
E
arly 
T
ermination
 
(Withdrawal)
 
visit and 
change from screening
.
 
The observed 
IOP data 
and 
change
-
from
-
baseline
 
(POD1) for 
the 
study eye will be summarized 
a
t 
each post
-
surgery visit
.
 
The data 
for s
lit lamp biomicroscopy 
examination 
endpoints will be summarized at each visit. 
The 
summary of 
change
-
from
-
baseline 
at each post
-
surgery visit
 
will be presented
 
for the study 
eye
.
 
 
Clinical Study Protocol:  CPN
-
301
 
Formosa Pharmaceuticals, Inc.
 
APP13007
 
 
Version 1.
3 
(Amendment 1)
 
CONFIDENTIAL
 
Page 
[ADDRESS_812253] ophthalmoscopic examination 
findings 
for the study and
 
non
-
study eye will be 
summarized 
at screening and 
Visit 6 (POD22)/
E
arly 
T
ermination
 
(Withdrawal)
.
 
 
Visual Acuity data will be summarized at each visit
.
 
The summary of change
-
from
-
baseline 
at 
each post
-
surgery visit
 
will be presented for the study eye
.
 
10.3.4
 
I
nt
erim 
A
nalysis
 
No interim analyses are planned for this study.
 
10.4
 
Sample Size Estimation
 
The assumption for the sample size determination was estimated using the Package Inserts of 
Durezol
®
, Lotemax
®
 
and Inveltys
®
 
and results from the APP13007 
P
hase 
2
 
study (CPN
-
201). 
The sample size for ACC 
count 
primary efficacy endpoint is based on the assumption of 26% of 
subjects in APP13007 group with ACC Count = 0 at POD8 and maintained through POD15 and 
12% of subjects in matching vehicle placebo group. The two
-
group chi
-
square test, with a two
-
sided significance level of 5% and 92% power, requires [ADDRESS_812254] the difference between APP13007 and placebo.
 
The same sample size using the assumption of 57% of subjects with Ocular Pain 
Grade = 0 at 
POD4 and maintained through POD15 in APP13007 group and 38% of subjects in placebo group 
will provide 95% power to detect the treatment difference.
 
With an estimated 5% dropout rate, this study will randomize approximately 185 subjects per 
tre
atment group for a total of approximately 370 subjects.
 
 
10.5
 
Level of Significance
 
Unless otherwise specified, all statistical tests will be two
-
sided and the statistical significance 
will be tested at the 5% level.
 
 
The primary 
efficacy endpoints
 
will be eval
uated using the 
f
ixed sequence testing described in
 
S
ection 
[IP_ADDRESS]
. 
 
10.6
 
Procedure for Accounting for Missing, Unused, or Spurious Data
 
If more than 5% of data points are missing 
at POD15 
in any treatment group, a tippi[INVESTIGATOR_612626].
 
Other 
missing data 
imputations 
will be 
detai
l
ed in the
 
SAP.
 
 
Clinical Study Protocol:  CPN
-
301
 
Formosa Pharmaceuticals, Inc.
 
APP13007
 
 
Version 1.
3 
(Amendment 1)
 
CONFIDENTIAL
 
Page 
81
 
of 
89
 
10.7
 
Procedure for Reporting Deviations from the Statistical Plan
 
Any deviations from the SAP will be described and a justification given in the final clinical study 
report.
 
10.8
 
S
ubjects to be Included in the Analysis
 
All efficacy analyses will be performed using the ITT population. In addition, the analysis of the 
primary efficacy endpoints will be performed using the PP population as a supportive analysis. 
AEs and other safety 
en
dpoints 
will be analyzed
 
using the 
S
afety 
P
opulation
.
 
Clinical Study Protocol:  CPN
-
301
 
Formosa Pharmaceuticals, Inc.
 
APP13007
 
 
Version 1.
3 
(Amendment 1)
 
CONFIDENTIAL
 
Page 
[ADDRESS_812255] Operating 
Procedures (SOPs) that meet the guidelines provided by [CONTACT_612667] (ICH) for Good Clinical Practice in clinical studies and applicable regulatory 
requirements.
 
11.1.[ADDRESS_812256]
s for the 
study will be approved by [CONTACT_612668]. In addition, the
 
APP13007
 
Investigator’s Brochure will be 
submitted to the IRB. Written IRB approval must adequately identify the protocol and informed 
consent form. Copi[INVESTIGATOR_202335], all 
correspondence with the IRB, and written 
approval from the IRB must be made available to the Sponsor (or designated Study Monitor).
 
Any modification of study procedures or amendments to the protocol must be approved by [CONTACT_612669]. In the event that a modification or 
amendment is considered by [CONTACT_612670], the Investigator will promptly notify his or her IRB, the Study Medical Monitor, and the 
CRO for Study Ma
nagement and Monitoring who will then notify the Sponsor.
 
Investigators will report all SAEs reported at their site to their IRB, as appropriate. 
 
11.1.4
 
I
nformed 
C
onsent 
P
rocess
 
Written informed consent will be obtained from each participant prior to any study
-
r
elated 
procedures being performed (prior to or on the Screening visit). A copy of the signed and dated 
informed consent document will be given to each 
subject
. The original signed and dated 
informed consent document must be maintained in the study files at
 
the investigative site and be 
available for the CRO for Study Management and Monitoring and the Sponsor or designee(s) to 
review. 
 
Clinical Study Protocol:  CPN
-
301
 
Formosa Pharmaceuticals, Inc.
 
APP13007
 
 
Version 1.
3 
(Amendment 1)
 
CONFIDENTIAL
 
Page 
[ADDRESS_812257]
’s aut
horized representative can call [ADDRESS_812258]
’s protected health information (PHI). This 
information may be obtained by t
he Sponsor, which includes any persons or companies that are 
working with, working for, or owned by [CONTACT_1034].
 
PHI may be given to the U.S. FDA 
D
epartment of Health and Human Services
 
agencies, other governmental agencies in the U.S., 
governmental agenci
es in other countries, and governmental agencies to which certain diseases 
(reportable diseases) must be reported.
 
11.2
 
Monitoring and Auditing Study Documentation
 
The Investigator(s)/institution(s)  will permit trial
-
related monitoring, audits, IRB review, and
 
regulatory inspection(s) by [CONTACT_60282] (such as tests 
performed as a requirement for participation in the study and other medical records) to the Study 
Monitor or the Sponsor or its designee.
 
11.2.[ADDRESS_812259]
 
into the study, a representative of the Sponsor 
or its designee such as the CRO for Study Management and Monitoring 
 
 and its Study Monitor will 
perform pre
-
study site evaluatio
n at each of 
the 
investigational study site
s
 
in person or remotely 
to:
 

 
Determine the adequacy of the facilities
 

 
Discuss with the Investigator(s) and other personnel their responsibilities about protocol 
adherence, and the responsibilities of the 
Sponsor or its designated Study Monitor and 
representatives. This will be documented in a Clinical Study Agreement between the Sponsor 
(Formosa Pharmaceuticals, Inc.) and the Investigator.
 

 
Confirm qualified staff are trained on the protocol, study processe
s and systems.
 

 
Confirm all supplies and study product are onsite and stored accordingly.
 

 
Collect any outstanding essential documents.
 
During the study, a monitor from the Sponsor or its designated CRO for Study Management and 
Monitoring 
 and its Study Monitor or representative will have 
regular contacts with the investigational site, for the following:
 

 
Provide information and support to the Investigator(s).
 

 
Confirm that facilities remain acceptable.
 

Clinical Study Protocol:  CPN
-
301
 
Formosa Pharmaceuticals, Inc.
 
APP13007
 
 
Version 1.
3 
(Amendment 1)
 
CONFIDENTIAL
 
Page 
84
 
of 
89
 

 
Confirm that the investigati
onal team is adhering to the protocol, that data are being 
accurately recorded in the eCRFs, and that study treatment accountability checks are being 
performed.
 

 
Perform source data verification. This includes a comparison of the data in the eCRFs with 
the 
subject
’s medical records at the investigational site, and other records relevant to the 
study. This will require direct access to all original records for each 
subject
 
(e.g. clinic charts 
or electronic records).
 

 
Record and report any protocol deviations n
ot previously sent to the Sponsor and the IRB.
 

 
Confirm the site has adequate supplies and study drugs.
 

 
Confirm AEs and SAEs have been properly documented on eCRFs and confirm that any and 
all SAEs have been forwarded to the Sponsor via the CRO for Study Ma
nagement and 
Monitoring and those SAEs that met criteria for reporting have been forwarded to the IRB.
 
The Study Monitor and other representatives at the CRO for Study Management and Monitoring 
will be available between visits if the Investigator(s) or oth
er staff needs information or advice.
 
11.2.2
 
A
uditing of 
S
ites and 
S
tudy 
D
ocumentation
 
Quality control and quality assurance may be performed before, during, and after the study by 
[CONTACT_13679]’s designee, such as the CRO for Study Management and Monito
ring and 
its Study Monitor
s
. Regulatory authorities in certain countries reserve the right to audit study 
sites following submission of data in regulatory applications. The Investigator may be given due 
notice of any intended audit by a regulatory body. By
 
[CONTACT_612671] 
1572, the Investigator acknowledges that these inspection procedures may take place and agrees 
to provide access to the required 
subject
 
records and other study documentation. Furthermore, 
the Investigator agrees to 
inform the Sponsor via the CRO for Study Management and 
Monitoring immediately of any known or suspected inspection by [CONTACT_177015]. If the Investigator 
does not comply with the protocol, GCP, or regulations, the Sponsor reserves the right to 
disqualify the
 
Investigator and/or site from the current or future protocols.
 
11.[ADDRESS_812260]
udy Monitor(s) from the 
CRO for Study Management and Monitoring for resolution. The study database will be updated 
Clinical Study Protocol:  CPN
-
301
 
Formosa Pharmaceuticals, Inc.
 
APP13007
 
 
Version 1.
3 
(Amendment 1)
 
CONFIDENTIAL
 
Page 
[ADDRESS_812261] no right to publish or 
present the results of this study without the prior written consent of the Sponsor.
 
 
Clinical Study Protocol:  CPN
-
301
 
Formosa Pharmaceuticals, Inc.
 
APP13007
 
 
Version 1.
3 
(Amendment 1)
 
CONFIDENTIAL
 
Page 
86
 
of 
89
 
 
R
EFERENCES
 
Apple
, D. J., K. D. Solomon, M. R. Tetz, E. I. Assia, E. Y. Holland, U. F. Legler, J. C. Tsai, V. 
E. Castaneda, J. P. Hoggatt, A. M. Kostick. 1992. "Posterior capsule opacification." 
Surv 
Ophthalmol
 
37(2): 73
-
116.
 
Aptel, F., C. Colin, S. Kaderli, C. Deloche, A.
 
M. Bron, M. W. Stewart, C. Chiquet and O. 
group. 2017. "Management of postoperative inflammation after cataract and complex ocular 
surgeries: a systematic review and Delphi survey." 
Br J Ophthalmol
 
101(11): 1
-
10.
 
Baudouin, C., A. Labbe, H. Liang, A. Pauly
 
and F. Brignole
-
Baudouin. 2010. "Preservatives in 
eyedrops: the good, the bad and the ugly." 
Prog Retin Eye Res
 
29(4): 312
-
334.
 
Clobex
®
. 2018. 
Clobex® (Clobetasol Propi[INVESTIGATOR_16847]) Spray 0.05% [Package Insert].
 
Fort Worth
-
TX: Galderma
-
Laboratores L.P.
 
Feldman, 
S. R. and B. A. Yentzer. 2009. "Topi[INVESTIGATOR_612627]: a review of newer formulations." 
Am J Clin Dermatol
 
10(6): 397
-
406.
 
Hengge, U. R., T. Ruzicka, R. A. Schwartz and M. J. Cork. 2006. "Adverse effects of topi[INVESTIGATOR_612628] ." 
J Am Acad Dermatol 
54(1): 1
-
15; quiz 16
-
18.
 
Jacob, S. E. and T. Steele. 2006. "Corticosteroid classes: a quick reference guide including patch 
test substances and cross
-
reactivity." 
J Am Acad Dermatol
 
54(4): 723
-
727.
 
Kaur, I. P., S. La
l, C. Rana, S. Kakkar and H. Singh. 2009. "Ocular preservatives: associated 
risks and newer options." 
Cutan Ocul Toxicol 
28(3): 93
-
103.
 
Leopold, I. 1985. "Nonsteroidal and steroidal anti
-
inflammatory agents." In 
Surgical 
Pharmacology of the Eye
, by [CONTACT_612672] M
 
and T. A., 83
-
133. [LOCATION_001], NY: Raven Press.
 
Olsen, E. A. and R. C. Cornell. 1986. "Topi[INVESTIGATOR_612629]
-
17
-
propi[INVESTIGATOR_16847]: review of its clinical 
efficacy and safety." 
J Am Acad Dermatol 
15(2 Pt 1
)
: 246
-
255.
 
Sparidans
, R.W., van Velsen S.G., de Roos M.P., Schellens J.H., Bruijnzeel
-
Koomen C.A., 
Beijnen J.H. 2010 
"
Liquid chromatography
-
tandem mass spectrometric assay for clobetasol 
propi[INVESTIGATOR_612630]
s with atopic dermatitis.
"
 
J Chromatogr B Analyt 
Te
chnol Biomed Life Sci
 
878(23):2150
-
4.
 
Temovate
®
. 2000. 
Clobetasol Propi[INVESTIGATOR_319051] 0.05% [Package Insert].
 
Research Triangle 
Park, NC: GlaxoWellcome Inc.
 
Clinical Study Protocol:  CPN
-
301
 
Formosa Pharmaceuticals, Inc.
 
APP13007
 
 
Version 1.
3 
(Amendment 1)
 
CONFIDENTIAL
 
Page 
87
 
of 
89
 
Tennant, J.L. 1978. "Cystoid maculopathy: 125 prostaglandins in ophthalmology." 
Current 
Concepts in Ca
taract Surgery: Selected proceedings of the fifth biennial cataract surgical 
congress, Section 3.
 
E. J.M St. Louis, MO: CV Mosby. 360
-
362.
 
van Velsen, S. G., M. P. De Roos, I. M. Haeck, R. W. Sparidans, C. A. Bruijnzeel
-
Koomen. 
2012. "The potency of clobet
asol propi[INVESTIGATOR_16847]: serum levels of clobetasol propi[INVESTIGATOR_612631] 0.05% clobetasol propi[INVESTIGATOR_612632]
s with severe atopic 
dermatitis." 
J Dermatolog Treat
 
23(1): 16
-
20.
 
 
 
 
 
 
 
Clinical Study Protocol:  CPN
-
301
 
Formosa Pharmaceuticals, Inc.
 
APP13007
 
 
Version 1.
3 
(Amendment 1)
 
CONFIDENTIAL
 
Page 
88
 
of 
89
 
A
PPENDIX 
A
 
CONTINGENCY PLANS RELATED TO THE COV
ID
-
19 
PANDEMIC
 
In
 
March 2020 
the 
FDA 
issued the 
Guidance: “Conduct of Clinical Trials of Medical Products 
during COVID
-
19 Pandemic”. 
 
Based on
 
the stated goal in th
is
 
FDA Guidance, the following plans 
may be 
implemented:
 
1.
 
When a clinical site 
plans to 
or has to 
close operations and visits c
annot
 
be 
scheduled 
per protocol
: 
 

 
If possible, s
chedule a
n Early Termination
/Withdrawal
 
visi
t before the clinical site close
s
.
 
o
 
Ask subject to s
top
 
the
 
study 
drug
, if 
before Visit 5 (POD15
)
.
 
o
 
Collect
ed
 
study drug and 
dosing 
diary.
 
o
 
Conduct 
the Visit 6 (
POD22
)
 
assessments.
 

 
A
 
Protocol Deviation 
is documented 
as “
Early Termination
/Withdrawal
 
visit performed 
because the study site closed for operations prior to 
completion of the study visits 
due 
to 
COVID
-
19 infection
-
control requirements”.
 
2.
 
When a subject 
c
annot
 
or d
oes
 
not 
want to return for an in
-
person visit:
 
 

 
The clinical site 
coordinator 
contact
s
 
the subject by [CONTACT_756] (or alternative method of 
communication) and ask
s
 
the subject to stop the study drug
, if before Visit 5 (POD15),
 
and 
collect
s
 
AE and concomitant medication information. 
 
o
 
The available information is entered in the Early Terminatio
n
/Withdrawal
 
section of the 
eCRF.
 
 
o
 
If 
before Visit 5 (POD15), the study coordinator
 
request
s
 
the subject to send the study 
drug bottle and dosing diar
y 
to the study coordinator at the clinical site.
 

 
The Investigator withdraws the subject
 
from the study and
 
consider
s
 
alternative methods of 
assessing the subject.
 

 
A 
Protocol Deviation 
is documented as “Subject withdrawn early (Early Termination) and 
the assessments for Visits X, Y and Z
 
were 
not performed because the subject could not or 
did not want to return
 
for an in
-
person visit due to COVID
-
19 infection
-
control 
requirements”.
 
Clinical Study Protocol:  CPN
-
301
 
Formosa Pharmaceuticals, Inc.
 
APP13007
 
 
Version 1.
3 
(Amendment 1)
 
CONFIDENTIAL
 
Page 
[ADDRESS_812262] IN THE NON
-
STUDY EYE
 
Location
 
Minimal
 
Mild
 
Moderate
 
Severe
 
Nuclear
 
Minimal Changes 
in nuclear zone
 
In the nuclear zone, 
the anterior and 
posterior embryonal 
nuclei are distinctly 
more opalescent 
(more visible) than 
normally seen, but 
the central clear zone 
is still easily 
distinguishable in its 
entirety
 
The nuclea
r zone is 
more uniformly 
opaque and the 
central clear zone 
between the anterior 
and posterior nuclei 
is not clearly visible. 
The posterior part of 
the zone is often 
more opaque.
 
The nuclear zone is 
densely opaque with 
more or less uniform 
nuclear opacity 
e
xtending to the 
edge of the nuclear 
zone; nuclear 
features are only 
partially visible, if at 
all.
 
Cortical 
 
Cataract involves 
<
 
⅛ of the 
circumference
 
Cataract involves 
⅛, 
but less than ¼, of the 
circumference.
 
Cataract involves ¼, 
but less than ½, of 
the 
circumference.
 
Cataract involves 
≥
 
½ of the 
circumference.
 
Posterior 
subcapsular
 
< 1 mm
 
≥ 1 mm, but < 2 mm 
 
≥2 mm, but < 3 mm
 
≥ 3 mm 
 
 